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“All things are poison and nothing is without poison; only the dose 
permits something not to be poisonous.”
Paracelsus (1493-1541)
Abstract
It has been estimated that, at any one time, more than one million people in the 
U.K. are taking the anticoagulant drug warfarin, for the treatment or prevention 
of venous thromboembolism. The incidence of life threatening haemorrhage, 
due to overdose, is approximately two per one hundred patient years. It is well 
known that there is great inter-individual variability in reaching and maintaining 
a therapeutic level of oral anticoagulants, in part, due to the combined effect of 
gender, age, body size and drug interactions.
In recent years, single nucleotide polymorphisms (SNPs) have been identified, 
which significantly reduce the amount of warfarin required for an individual to 
reach a therapeutic level. Consequently, the optimum dose of warfarin can be 
predicted in a higher percentage of patients using an algorithm, which includes 
pharmacogenomic information rather than one with clinical and demographic 
data alone.
The aim of this study was to create two rigorous, composite algorithms, one 
clinical and one pharmacogenetic, which combined as many influencing factors 
as possible, in an effort to improve the predictability of warfarin dosing beyond 
that of other published studies to date. The study was carried out using three 
groups of subjects, after obtaining ethical committee approval and informed 
consent. Group 1 subjects (n=12) were healthy, non-warfarin treated laboratory 
staff, whose DNA was used to optimise the DNA extraction procedure. Group 2 
subjects (n=207) consisted of warfarin patients, who had had a stable 
therapeutic International Normalised Ratio (INR) for at least two months. A 
comprehensive list of clinical and demographic data was obtained from each 
patient, as well as DNA samples for SNP analysis of the VKORC1, CYP2C9 
and CYP4F2 genes. Group 3 subjects (n=20) comprised of pre-warfarinised 
patients who provided the same data as in group 2. In addition, venous blood 
samples were obtained for the measurement of the baseline levels of the 
vitamin K dependent coagulation factors and albumin. The stable warfarin dose 
for each of the group 3 patients was obtained retrospectively, after several 
weeks of warfarin therapy.
The two algorithms were then constructed using the data from a random 
selection of group 2 patients (n=160). These were then used to predict the 
warfarin dose of the remaining patients in the group (n=47). By plotting the 
predicted dose against the actual stable dose, the percentage predictability of 
the new algorithms was calculated. In addition, the predictability of eleven 
previously published algorithms, eight pharmacogenetic and three clinical, was 
calculated using the same 47 patients. The clinical algorithm from this study 
showed the lowest predictability (R2=0.188) when compared to the three 
published algorithms (R2=0.203-0.268). However, the pharmacogenetic 
algorithm was able to account for a higher proportion of the warfarin dose 
(R2=0.553) than any of the other eight published algorithms (R2=0.383-0.525).
In the group 3 patients, no relationship was demonstrated between the warfarin 
dose and either the albumin levels or the baseline levels of the vitamin K- 
dependent coagulation factors, with the exception of factor IX, which showed a 
negative correlation.
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Chapter 1
1.1 Introduction
It is estimated that between 500,000 and 1 million people in the United Kingdom 
are currently being prescribed oral anticoagulant therapy (OAT) and of these 
warfarin is the main drug of choice among clinicians at the present time in the 
treatment of venous thromboembolism (VTE) (Greaves, 2005; Baglin et a/, 
2006).
Despite having few side effects, the commonest complication by far is the risk of 
haemorrhage, due to over-anticoagulation and which, if severe enough, can be 
life threatening. The rate of these occurrences is estimated to be in the order of 
2 per 100 patient years, with minor bleeding being more common. Conversely, 
under-anticoagulation may lead to the development of thrombosis or 
propagation of an existing thrombus, either of which may also be life threatening 
(Palareti et al, 1996). There are several causes for such serious adverse 
events; numerous factors are responsible for either potentiating or attenuating 
the pharmacological effects of OAT. The therapeutic range between over- and 
under-anticoagulation is narrow and compliance can be problematic, especially 
in elderly patients. Consequently, it has been estimated that patients are only 
within the target range between 50-70% of the time, even under the best 
available management (Greaves, 2005).
In order to fully understand the reasons behind the design and implementation 
of this study, the thesis will begin with an overview of the haemostatic 
mechanism and the pathophysiology of thromboembolism. After this, there will 
be a detailed review of warfarin, firstly through its history, pharmacology and 
dose monitoring, followed by a comprehensive evaluation of the clinical, 
demographic and genetic factors that affect OAT. Finally, the aims and 
objectives of this study will be discussed, in order to explain the design and 
methodology used in the ultimate development of one clinical and one 
pharmacogenetic algorithm for the prediction of the warfarin dose in patients 
prior to the commencement of treatment.
1
1.2 The haemostatic mechanism
The coagulation cascade and platelets are vital mechanisms for the prevention 
of haemorrhage. Injury to the blood vessel endothelium results in the exposure 
of extravascular structures, with the consequent activation of platelets and the 
coagulation pathway. This ultimately forms a stable thrombus, consisting mainly 
of an insoluble fibrin mesh and platelets, which occludes the vascular damage 
(Dahlback, 2000).
The coagulation cascade involves a series of enzymatic reactions involving 
inactive zymogens and other cofactors, which are activated sequentially by 
proteolytic cleavage and result in an amplified chain reaction leading to the 
production of fibrin (Norris, 2003). This pathway is controlled simultaneously by 
the fibrinolytic system, whereby a number of negative feedback reactions 
involving natural anticoagulants prevent further activation of the cascade and 
therefore limit the propagation of the thrombus. Thrombosis occurs when one or 
more stages in the coagulation mechanism and/or the fibrinolytic system are 
affected by genetic or clinical factors, leading to the production of a thrombus, 
either in the absence of vascular injury or an inability to limit thrombus 
propagation as a result of vessel wall damage (Kroegel & Reissig, 2003). 
Traditionally, the coagulation cascade has been described by dividing it into 
three sections; the extrinsic (or tissue factor) pathway, the intrinsic (or contact 
factor) pathway and the common pathway and all the proteins involved are 
denoted by Roman numerals. Most of these proteins are serine proteases, with 
the exception of three cofactors, [factor V, factor VIII and high molecular weight 
kininogen (HMWK)] and one transglutaminase, factor XIII (Norris, 2003).
The intrinsic pathway involves the conversion of inactive factor XII to its active 
form (XIla) by contact with a negatively charged surface, particularly collagen, 
which is exposed during vascular injury. This in turn causes the activation of 
factor XI to Xla and, together with the cleavage of HMWK, results in the 
formation of factor IXa (Fig1.1) (Norris, 2003).
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The extrinsic pathway is initiated when tissue factor (TF), a cellular membrane- 
bound protein, becomes exposed to the plasma following vascular damage and 
binds to factor VII, forming the TF-Vlla complex, the most potent activator of the 
coagulation system. This complex then activates factor X to Xa, converging with 
the product of the intrinsic pathway (Norris, 2003).
The overall result of both pathways is to produce what is known as the ‘tenase’ 
complex, in which IXa, together with Villa, calcium and phospholipid, combine 
to activate factor X to Xa, (which is also produced by TF-Vlla). The ‘tenase’ 
complex is fundamental to the overall function of the coagulation cascade and 
deficiency in either factor VIII or factor IX results in one of two severe 
haemorrhagic disorders (haemophilia A and B respectively) (Norris, 2003). The 
‘tenase’ complex is responsible for the formation of the prothrombinase 
complex, which consists of Xa, the non-enzymatic cofactor Va, calcium and 
phospholipid, which in turn activates factor II (prothrombin) to lla (thrombin). 
Thrombin has a central role in the whole haemostatic mechanism, being 
responsible for the upstream activation of factors V, VIII, IX and XI, as well as 
platelets and the fibrinolytic protein C (Norris, 2003). Nonetheless, a pivotal 
function of thrombin is at the end of the coagulation cascade, involving the 
conversion of factor I (fibrinogen) to factor la (fibrin). However, fibrin is produced 
as soluble monomers and consequently forms an unstable thrombus. The 
monomers are cross-linked to form insoluble fibrin by the action of factor Xllla, 
which itself is activated by thrombin.
Although there are negative feedback loops within the coagulation cascade, 
mainly mediated by thrombin, the antithesis of fibrin clot formation is the 
fibrinolytic system. Using a similar notation to the coagulation pathway, the 
inactive zymogen plasminogen is activated either intrinsically (by FXIIa and 
kallikrein) or extrinsically by tissue plasminogen activator (t-PA) from the 
endothelium. The activated product, plasmin, is a serine protease which 
hydrolyses peptide bonds not only in fibrin, thereby degrading a thrombus, but 
also in fibrinogen, FV and FVIII, leading to their inactivation (Hoffbrand and 
Pettit, 1993).
5
A second pivotal pathway in fibrinolysis is the formation, by thrombin and 
thrombomodulin, of the activated protein C/protein S (PC/PS) complex, which 
not only inactivates t-PA inhibitors but more importantly it is responsible for the 
inactivation of the coagulation cofactors FVa and FVIIIa, resulting in further 
suppression of thrombus formation. In addition, activated FX (FXa) is inhibited 
by a glycoprotein, protein Z (PZ), which has a similar structure to PC and PS 
(Broze & Miletich, 1984).
1.3 The vitamin K cycle
Vitamin K was first suggested as being involved in the coagulation mechanism 
by Henrik Dam in the 1930’s, who noticed that chickens fed on a fat-free diet 
developed spontaneous haemorrhages (Lindh, 2009). Dam postulated the 
existence of a fat-soluble vitamin (designated vitamin K, from the German word 
‘Koagulation’) and, following its subsequent purification and the determination of 
its molecular structure, Dam was awarded the Nobel Prize for medicine with 
Edward Doisy in 1943.
Within the haemostatic mechanism, several factors produced in the liver (II, VII, 
IX, X, PC, PS and PZ) require the presence of vitamin K in order to become 
functional molecules and are known as the vitamin K-dependent factors 
(Hoffbrand and Pettit, 1993). A reduced form of vitamin K (vitamin Ki 
dihydroxyquinone) acts as an electron donor to the enzyme y-glutamyl 
carboxylase (GGCX) and, together with carbon dioxide and oxygen, causes the 
carboxylation of glutamic acid residues in the active site of the haemostatic 
proteins, producing a negatively-charged complex (fig. 1.2). This enables them 
to undergo conformational changes when activated by calcium cations, thereby 
allowing them to bind to co-factors present on phospholipid surfaces (Ansell et 
al, 2008). As a result, the reduced vitamin K is oxidised to vitamin K epoxide 
and must undergo two electron reductions in order to be regenerated 
(McDonald et al, 2009). This is mediated by the enzyme vitamin K epoxide 
reductase (VKOR), which is encoded for by the gene vitamin K epoxide 
reductase complex subunit 1 (VKORC1), and is the target molecule for the 
action of warfarin.
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1.4 The pathophysiology of venous thromboembolism (VTE)
In 1856, Virchov proposed three major causes of VTE, which came to be known 
as Virchov’s triad (Virchov, 1856). These were hypercoagulability, changes in 
the vessel wall and haemodynamic defects resulting in stasis. Although it has 
been modified over the years, the triad is still the basis of our understanding of 
VTE today (Sevitt, 1974).
Two distinct but interrelated aspects of VTE are pulmonary embolism (PE) and 
deep vein thrombosis (DVT), which are major causes of morbidity and mortality 
within the developed world. The incidence of these two diseases has not 
decreased significantly over several decades, despite improvements in 
diagnosis and treatment (Kroegel and Reissig, 2003) and it is estimated that 1 
in 1000 people are affected every year in the UK alone (Dahlback, 2000). The 
thrombus in VTE is mainly composed of fibrin, derived ultimately from activation 
of the coagulation cascade, some trapped erythrocytes and a small layer of 
platelets (Lopez et al, 2004), which is attached to the vessel wall. However, 
VTE is seldom associated with vessel wall damage (as occurs in arterial 
thrombosis), indicating that the coagulation mechanism must be activated by 
other means (Lopez & Chen, 2009). There is general agreement that VTE 
involves the initiation of coagulation via TF, but most research has involved the 
use of animal models with vessel wall damage (Esmon, 2009). However, other 
studies have shown that TF can originate from blood cells, especially 
monocytes, or from leukocyte-derived microparticles, which not only contain TF 
but also the cell-cell adhesion molecule P-selectin (Myers et al, 2003). Inhibition 
of P-selectin has been shown to inhibit thrombus formation (Myers et al, 2005) 
and, as it is important for platelet function and platelet-leukocyte interaction, it 
has been postulated that it is important for the production of the platelet 
component in the fibrin-dominant layer of a thrombus and therefore may confer 
stability to the clot (Esmon, 2009). Inflammation has also been implicated in 
thrombus formation, whereby there is localized activation of the vessel wall 
endothelium, causing the release of von Willebrand factor and P-selectin from 
Weibel-Palade bodies. However, both molecules remain attached to the 
endothelial surface and attract leukocytes, which in turn shed microparticles
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from their membrane and result in activation of the coagulation pathway (Lopez 
and Chen, 2009).
Two major contributors to the occurrence of VTE are stasis and hypoxia, due to 
either dysfunctional venous valves (Esmon, 2009), an increase in the 
haematocrit (Hamer et al, 1981) or possibly the down regulation of two 
fibrinolytic proteins, thrombomodulin and the protein C receptor (Brooks et al, 
2009). Endothelial cell components such as these are important in many 
haemostatic pathways and, when blood moves from larger to smaller vessels, 
there is a dramatic increase in the efficacy of these proteins, including TF 
pathway inhibitor (Esmon, 1989). This is partly due to an increase in the 
endothelial cell surface exposed to the blood. However, if venous stasis occurs, 
the blood stays in the large vessels for longer, where the natural anticoagulant 
properties are not as efficient as in the microcirculation, due to a reduced ratio 
of the endothelial surface to blood volume (Esmon, 2009). It has also been 
postulated that venous stasis results in the oxygen desaturation of 
haemoglobin, resulting in an hypoxic insult to the local endothelium and the 
spontaneous expression of P-selectin (Closse et al, 1997).
The third part of Virchov’s triad, hypercoagulability, has been the area of 
greatest advances in the past two decades. The discovery of the factor V 
Leiden genetic mutation (Dahlback et al, 1993) and activated protein C (APC) 
resistance has helped to explain 20-40% of all cases of hereditary VTE, 
predominantly in populations of Caucasian origin (Dahlback, 2000). In these 
cases, the FV molecule produced by a single point mutation has arginine 506 
replaced by glutamine, resulting in the loss of one of the activated protein C 
cleavage sites. As a consequence, the mutated FV is not sufficiently 
deactivated and continues with full procoagulant activity. The risk of VTE in 
cases of heterozygous APC resistance is approximately 5-10 fold, but increases 
dramatically in homozygotes to 50-100 fold (Dahlback, 2000).
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The second commonest genetic factor that confers hypercoagulability is the 
prothrombin 20210 gene, which was first described in 1996 by Poort et al. The 
mutation causes an increase in the plasma prothrombin concentration, which 
therefore not only allows for an increased production of thrombin, but also acts 
as an inhibitor of protein C. The 20210 gene is found in 2% of Caucasians and 
increases the risk of VTE by 3-5 fold (Dahlback, 2000). Changes in the levels of 
other haemostatic proteins have also been implicated in an increased risk of 
VTE; increased concentrations of factors VIII, VII and von Willebrand factor 
(Bertina, 2004) and decreases in protein C, protein S and antithrombin III 
(Dahlback, 2000) have all been shown to cause variable increases in the risk of 
thrombogenesis. Many acquired disorders and demographic factors are 
associated with an increased propensity for VTE. In the antiphospholipid 
syndrome, autoantibodies, or lupus anticoagulant, can cause both arterial and 
venous thrombosis. Antibodies are produced which target p2-glycoprotein 1 and 
occasionally prothrombin, and can also be responsible for an increased risk of 
miscarriage by forming thrombi in the placental circulation (Dahlback, 2000).
The risk of VTE increases with age but the exact reason is uncertain (Esmon, 
2009). However it is known that, in the elderly, there is an increase in the 
concentrations of some coagulation factors without a concomitant increase in 
anticoagulant proteins, as well as an increase in D-dimer levels, which suggests 
hypercoagulability (Lowe et al, 1997). Furthermore, there is an increased risk of 
immobility due to frailty and illness, leading to venous stasis (Esmon, 2009) as 
well as an increase in the number of co-morbidities (Silverstein et al, 2007). 
Malignancy increases the danger of venous thrombosis and approximately 20% 
of cases presenting with VTE have an underlying tumour (Lopez et al, 2004). In 
these cases, VTE risk is increased 6-10 fold (Bick, 2003) and is thought to be 
due to procoagulant particles containing TF being produced by tumour cells and 
initiating a coagulation response (Dvorak et al, 1981). Additionally, some 
tumours compress blood vessels and may lead to an increased risk of stasis 
(Esmon, 2009).
In summary, VTE is considered to be a multigenic disease (Dahlback, 2000)
and the risk factors are known to act synergistically. For example, obesity and
oral contraceptives are both associated with an increased risk of thrombosis (2
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fold and 4 fold, respectively), however, when present together, the increased 
risk is far greater than that of the two combined (Abdollahi et al, 2003).
1.5 The anticoagulant drug warfarin
Warfarin [(RS)-4-hydroxy-3(-3-oxo-1-phenylbutyl)-2H-chromen-2-one] is a 
synthetic derivative of dicoumarol (4-hydroxycoumarin), which is in turn derived 
from coumarin, found naturally in many plants. It is one of a number of 
coumarin-based drugs, which has been used for many years in the field of 
antithrombotic therapy. Warfarin is prescribed both as a treatment for existing 
DVT and PE, in order to prevent further propagation and/or embolism of the 
thrombus, and prophylactically in cases where thrombosis is likely to occur, 
such as in patients with atrial fibrillation (AF), mechanical heart valves or with a 
genetic propensity for thrombus formation, also known as hereditary 
thrombophilia (Kamali et al, 2000b). At sub-therapeutic levels, the patient is at 
risk from propagation of the existing thrombus or the formation of new thrombi; 
at super-therapeutic levels, there is a high risk of haemorrhage and the rate of 
life-threatening bleeding is approximately two per one hundred patient years, 
with minor bleeding being more common (Palareti etal, 1996).
1.5.1 The history of warfarin
The serendipitous findings that led ultimately to the introduction of oral 
anticoagulants began in 1924, when Frank Schofield described a new fatal 
haemorrhagic disease in cattle, which had occurred almost simultaneously in 
North Dakota, USA and Alberta, Canada (Schofield, 1924). He traced the cause 
to the ingestion of sweet clover hay spoiled by the mould Aspergillus and the 
disease became known as ‘sweet clover disease’. Schofield also showed that it 
wasn’t the Aspergillus itself that caused either the bleeding or the prolonged 
blood clotting time and that the disease manifested itself as a slow decrease in 
clotting ability over approximately 15 days, resulting in fatal internal 
haemorrhage between 30-50 days (Copeland & Six, 2009).
In 1931, Lee Roderick demonstrated that the problem was caused by a marked 
reduction in one of the coagulation proteins, prothrombin but that the effects 
could be corrected with a bovine blood transfusion (Roderick, 1931). Moreover,
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there was no effect on any of the other coagulation constituents known at that 
time, namely calcium, fibrinogen and platelets. Late in 1932, Karl Link was 
invited to set up a research team at the University of Minnesota, in order to 
study Roderick’s findings in more detail. Within a few weeks, Link was visited by 
a farmer, Ed Carlson, who arrived with a dead heifer, a milk churn full of non­
clotted blood and a large sample of spoilt sweet clover. By 1939, one of the 
team, Harold Campbell, had isolated and purified 6mg of crystalline dicoumarin 
from the samples (Campbell, 1941). Two years later, Mark Stahman purified 
1.8g of dicoumarin and showed that spoilage of sweet clover by Aspergillus 
mould resulted in the oxidation of coumarin to 4-hydroxycoumarin (Link, 1959). 
Furthermore, in the presence of formalin, a product of additional decay, the 4- 
hydroxycoumarin was converted to 3,3’methylenebis-(4 hydroxycoumarin) or 
dicoumarin. Link patented the final product under the trade name dicoumarol.
The team tested dicoumarol on various animal species and made several 
observations, which still hold relevance for anticoagulant therapy today (Link, 
1943). Firstly, they noted that there was a considerable delay between ingestion 
and effect on the clotting mechanism and that repeated administration produced 
a cumulative response. Secondly, they found that reduced hepatic and renal 
function significantly influenced the intensity and duration of action. 
Furthermore, other drugs such as salicylates potentiated the action of 
dicoumarol and dietary vitamin K was shown to affect the intensity and duration 
of its action. Within days of publishing these findings, the Mayo Clinic requested 
samples of dicoumarol and, within 3 months, trials had shown its effect of 
increasing the blood clotting time in 6 human subjects (reviewed by Copeland 
and Six, 2009).
During this time, Link had also become aware of the similarities in biochemical 
structure between dicoumarol and vitamin K, a compound discovered by Henrik 
Dam in 1935 and synthesized by Edward Dosey in 1939. In a series of animal 
experiments, he demonstrated that vitamin K could reverse the anticoagulant 
effect of dicoumarol (Link, 1943). In 1942, field trials were conducted on 
dicoumarol for its use as a rodenticide, but it was found not to be potent enough 
(Link, 1959), so Link assembled a team to reappraise dicoumarol analogues 
and, in 1948, patented a more potent alternative with Mark Stahman and Lester
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Scheel (Link, 1959). This was named warfarin, an acronym derived from the 
Wisconsin Alumni Research Foundation (WARF) and the ending “-arin”, 
denoting its link with coumarins and it was promoted as a rodent poison.
In 1950, Link recommended the use of the sodium salt of warfarin for use in 
clinical medicine, as it was at least five-times more potent than dicoumarol. 
Understandably, there was great reluctance from the medical profession to use 
a substance that had been promoted as a rat poison on human patients; 
however two events occurred soon after which would change the situation. In 
1955, a US navy inductee attempted suicide by ingesting 567mg of warfarin 
over a period of 6 days. He was subsequently treated with blood transfusions 
and intravenous vitamin K, and made a full recovery (Holmes & Love, 1952). In 
the same year, Colonel Byron Pollock, who was stationed at the Fitzsimons 
Army Hospital in Denver, presented a paper describing his use of warfarin on 
100 patients suffering from either myocardial infarction or DVT (Pollock, 1955). 
One of the patients was the then President, Dwight D. Eisenhower, following a 
heart attack and, within a year, warfarin was declared the anticoagulant of 
choice in American hospitals (reviewed by Lindh, 2009).
1.5.2 The pharmacology of warfarin
From a pharmacological perspective, warfarin is more complicated than many 
other drugs in use today. Its mode of action and elimination, interaction with 
other drugs, narrow therapeutic range, susceptibility to genetic influences and 
severe consequences of over- and under-dosing make it difficult to manage 
clinically. As a result, patients taking warfarin require frequent laboratory 
monitoring (see section 1.5.3) as well as clinical experience and a sound 
theoretical knowledge of the drug’s actions (Lindh, 2009).
Warfarin consists of a racemic mixture of two enantiomers, R and S (Figure 
1.3). S-warfarin is three to five times more potent in its anticoagulant effect and 
has a plasma half-life of approximately 29 hours, compared to R-warfarin, which 
has a half-life of 45 hours (Ansell et al, 2008). Warfarin is administered orally, 
usually as a sodium salt, and is readily absorbed from the Gl tract, reaching 
maximum plasma levels within two hours (Gage & Milligan, 2005). Here, it is 
99% bound to plasma proteins, mainly albumin, and it is the unbound drug that
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is pharmacologically active (Beinema et al, 2008). The maximum effect of any 
one dose may occur up to 48 hours after administration and may continue for 
several days (D’Andrea et al, 2008).
The two enantiomers are metabolised by different pathways in the liver. S- 
warfarin is metabolised to S-7 hydroxywarfarin by the CYP2C9 enzyme of the 
cytochrome P450 system (Rettie et al, 1992) and is excreted in the bile (Ansell 
et al, 2008). R-warfarin, on the other hand, is metabolised by three different 
cytochrome enzymes, CYP1A1, CYP1A2 and CYP3A4, and is excreted via the 
kidneys (Gage & Milligan, 2005).
Figure 1.3 S- and R-enantiomers of warfarin.
* denotes the chiral carbon atom (adapted from Lindh, 2009)
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The mode of action of warfarin is the inhibition of the vitamin K epoxide 
reductase enzyme (VKOR) in the vitamin K cycle (see fig 1.2), thus preventing 
the reduction of vitamin Ki epoxide to vitamin Ki dihydroxyquinone (McDonald 
et al, 2009). When approximately 70% of the VKOR molecules have been 
inactivated in the liver by warfarin, the supply of vitamin Ki dihydroxyquinone 
available to y glutamyl carboxylase (GGCX) is no longer sufficient for the 
carboxylation of the coagulation factors to take place (Lindh, 2009). This results 
in the secretion into the circulation of large amounts of uncarboxylated factors II, 
VII, IX and X, which are unable to participate in the coagulation cascade and 
are known as PIVKA proteins (proteins induced by vitamin K absence or 
antagonism) (Hoffbrand and Pettit, 1993). The overall reduction in the activity of 
the coagulation mechanism takes place over several days following initiation of 
warfarin therapy, depending on the half-life of the clotting factors affected. 
Factor VII shows low levels of functionality within 48 hours, due to a half-life of 6 
hours, whereas the potency of factors II and X may take several more days to
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be sufficiently suppressed. In addition, warfarin rapidly reduces the 
carboxylation of the fibrinolytic proteins C, S and Z, which leads to the 
paradoxical state of hypercoagulability in the first few days of therapy (Reynolds 
et al, 2007).
1.5.3 The laboratory control of warfarin therapy
The laboratory test for the monitoring of oral anticoagulant therapy is based on 
the prothrombin time (PT), which measures the activity of factors I, II, V, VII and 
X (Hall & Malia, 1991). The patient’s plasma is incubated with tissue 
thromboplastin in vitro, in order to simulate the activation of the coagulation 
cascade in vivo. Calcium ions, in the form of CaCb, are then added and the time 
taken for a fibrin clot to form is measured. In order to standardise the control of 
anticoagulant therapy, it is necessary to be able to compare results between 
different laboratories, not only because of the wide variety of automated 
methods used, but also because of the numerous types and batches of 
thromboplastin available, each with differences in their sensitivity. 
Consequently, results are expressed as the International Normalised Ratio or 
INR (WHO, 1983). All thromboplastins are now calibrated against a WHO 
standard and their sensitivity is expressed as the International Sensitivity Index 
(ISI), where the primary standard has an ISI of 1.0. The manufacturer must 
calibrate every batch of thromboplastin and mark the ISI value clearly on the 
reagent label.
Within each laboratory, a normal range for the PT must be established every 
time a new batch or brand of thromboplastin is used, or when an automated 
system is replaced. This is determined by measuring the PT of at least 20 
healthy adults and calculating the geometric mean or Mean Normal Prothrombin 
Time (MNPT) (Hall and Malia, 1991). This is used for the calculation of all 
subsequent INRs using the formula:
INR =
r  ^
Patient PT 
MNPT
V  J
ISI
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1.5.4 Clinical indications for anticoagulation
In the UK, indications for the commencement and maintenance of OAT have 
been proposed by the British Committee for Standards in Haematology (BCSH, 
1998) and revised (BCSH, 2006) and broadly fall into two categories. Firstly, 
OAT is indicated in patients who have an increased risk of thrombosis i.e. AF 
and/or mechanical prosthetic heart valves, as well as patients with an inherited 
thrombophilia or following orthopaedic surgery (Baglin et al, 2006). Secondly, 
patients require OAT if they have an existing thromboembolic event, such as PE 
or DVT, in order to prevent further propagation of the thrombus and also to 
reduce the risk of embolisation.
In either case, therapy may be maintained for a short period of time, usually 3-6 
months, or life-long, depending on the risk of thrombus development. In 
addition, the level of anticoagulation needed for prevention or prophylaxis, as 
determined by the target INR, needs to be balanced against an individual’s risk 
of developing haemorrhagic complications (Dahlback, 2000).
Therapeutic monitoring is guided by maintaining the INR within +/- 0.5 units of 
the target (i.e. target 2.5, range 2.0-3.0 or target 3.5, range 3.0-4.0), as 
recommended by the BCSH (BCSH, 1998) and is summarised in Table 1.1.
1.5.5 Adverse effects of warfarin
Warfarin is one of many common drugs that has been linked to fatal medication 
errors in primary care (Baglin et al, 2006) and is near the top of a list of ten 
drugs associated with prescribing or dispensing errors in secondary care. In the 
UK, between 1990 and 2002, there were 480 cases of harm or near harm 
involving anticoagulant therapy, including 92 deaths directly attributable to 
warfarin; in addition, warfarin is in the top ten of drugs cited in errors leading to 
litigation against NHS Trusts (Baglin et al, 2006). The commonest cause of 
morbidity and mortality during warfarin therapy is due to haemorrhage, mainly 
due to accidental overdose (especially in the elderly), drug interactions or a high 
initiation dose and bleeding may manifest as bruising, haemoptysis, epistaxis, 
haematuria or melaena (Reardon etal, 1995).
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Table 1.1 Indications for oral anticoagulant therapy, target INR 
and recommended duration of therapy.
Indication Target INR Duration
PE DVT 2.5 3-6 months
Recurrent PE/DVT  
Inherited thrombophilia 
Atrial fibrillation 
Cardiomyopathy 
Antiphospholipid 
syndrome 
Arterial grafts 
Coronary artery 
thrombosis
2.5 lifelong
DVT/PE whilst on OAT 3.5 lifelong
Aortic mechanical heart 
valves
Mitral mechanical heart 
valves
2.5 or 3.0 
3.0 or 3.5
lifelong
BCSH, 2006.
PE = pulmonary embolism 
INR = International Normalised 
Ratio
OAT = oral anticoagulant therapy 
DVT = deep vein thrombosis
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The risk of haemorrhage during long term OAT has been estimated to be 
between 1-15% per year (Oden and Fahlen, 2002); however, the risk of major 
bleeding is greatest at the start of treatment rather than during maintenance, 
mainly due to the fact that the patient’s stable therapeutic dose is unknown 
(Gage and Eby, 2003; Linkins et al, 2003). In one study, 7% of patients (n=162) 
had some form of bleeding episode within one month of commencing warfarin 
therapy, which increased to 12% within two months (Beyth et al, 2000).
Heparin is administered when anticoagulation is required during pregnancy, due 
to the adverse effects of warfarin on the foetus. Firstly, warfarin is able to pass 
through the placental barrier and may cause foetal haemorrhage due to the 
immaturity of the foetal liver (BCSH Guidelines, 1998). This has been 
associated with spontaneous abortion and neonatal death (Schardein & Macina,
2007). Secondly, warfarin is a teratogen and the incidence of birth defects in 
foetuses exposed to it in utero has been estimated to be about 5% (Schardein & 
Macina, 2007). Known as foetal warfarin syndrome (FWS), these defects 
include skeletal abnormalities (particularly following exposure in the first 
trimester) and central nervous system disorders, such as seizures and eye 
defects, in the second and third trimesters. FWS has also been associated with 
a decrease in birth weight and developmental retardation (Loftus, 1996).
1.5.6 Initiation of OAT
There are several initiation dosing regimens and the decision as to which is 
used can depend on multiple factors. These include the age, gender and body 
size of the patient, as well as concomitant drugs and the morbidity and mortality 
implications of the thrombotic event. The positive diagnosis of a thrombotic 
event, such as PE or DVT, usually requires higher initial doses of OAT than in 
cases of prevention (i.e. AF), with concomitant once-daily administration of 
subcutaneous low molecular-weight heparin (LMWH) (BCSH, 1998).
Fennerty et al (1984) proposed a dosing schedule, tailored to each patient’s 
INR on days 2 and 3, using an initial dose of 10mg on the first day (Appendix 
IX). A prediction of the final maintenance dose was made according to the INR 
response on day 4 and all the patients in the study (n=50) were within the
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therapeutic range by day 6. The study showed a close correlation between the 
predicted and actual maintenance dose (r=0.867 p<0.001).
Similarly, a study by Kovacs et al (2003) showed that a 10mg initiation protocol 
not only resulted in patients achieving the therapeutic INR 1.4 days earlier than 
5mg (p<0.001), but that 83% reached the therapeutic range by day 5 (n=104) 
as opposed to 46% with the 5mg dose (n=97, p<0.001). There was no 
significant difference between the two groups in the number of INRs >5.0 and 
the study concluded that, like Fennerty et al (1984), a 10mg dosing protocol 
was superior to 5mg due to the fact that the therapeutic INR can be achieved 
more quickly.
While the Fennerty and Kovacs regimens proved to be useful for quickly 
reaching a stable therapeutic INR for in-patients with an existing thrombus, Tait 
and Sefcick (1997) designed an initiation protocol which was less intense, due 
to the fact that in many cases anticoagulant therapy is prophylactic with no 
immediate threat of thrombosis, especially in patients with AF. Moreover, a 
rapid induction protocol in elderly patients, using high doses of warfarin, has a 
high risk of over-anticoagulation and therefore haemorrhage. The Tait protocol 
(Appendix X), using an induction warfarin dose of 5mg for 4 days (n=36), was 
compared with that of Fennerty et al, with a loading dose of 10mg (n=33). The 
time taken to reach the therapeutic INR was similar in both groups; however, 
with the new regimen, there were fewer INRs >4.5 (2/36 vs. 9/33) as well as a 
more accurate prediction of the final maintenance dose (r=0.985). Similarly, 
Crowther et al (1999) found that more patients achieved a therapeutic INR 
within five days (21/32) on the 5mg induction dose than those on the 10mg 
dose (5/21, p<0.003).
The original guidance for the initiation of warfarin therapy in the UK (BCSFI, 
1998) recommended an initial oral dose of 10mg (Fennerty et al, 1984), with a 
subsequent change in dose for days 2, 3, and 4, depending on the INR 
response. This has been superseded (BCSFI, 2006) by taking a more cautious 
approach; for outpatients not requiring rapid anticoagulation, a smaller loading 
dose of 2mg (Oates et al, 1998) or 3mg (Janes et al, 2004) is recommended, as
these achieve the therapeutic INR within 3-4 weeks, while significantly reducing
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the risks of haemorrhage through over-anticoagulation. In cases where more 
rapid anticoagulation is required, 5mg doses are recommended, as compared 
to 10mg, especially in cases of liver disease, cardiac failure, patients over 60 
years old and those at risk from haemorrhage (BCSH, 2006).
1.5.7 Reversal of OAT
The risk of haemorrhage with OAT has been shown to significantly increase 
when the INR reaches 5.0 or higher in a study of patients with mechanical heart 
valves, with 2 adverse events per 100 patient years for INRs between 2.5-4.9, 
rising sharply to 75 events per 100 patient years for INRs >6.5 (Cannegeiter et 
al, 1995). The mode of intervention for the reversal of excessive anticoagulation 
is dependent on the INR and the presence or absence of bleeding and its 
severity. The initial recommendations regarding the management of 
hypercoagulable states (BCSH, 1998) have since been revised and modified 
(BCSH, 2006) and these are summarised in Table 1.2.
1.6 Factors affecting warfarin therapy
1.6.1 The pharmacogenetics of warfarin treatment
Pharmacogenetics is the study of variations in the DNA sequence of a patient in 
relation to their response to a particular drug, and therefore its safety and 
efficacy (French et al, 2010). It is a rapidly developing field of science for 
predicting both the dose requirements and patients’ responsiveness to various 
drugs and can ultimately help clinicians make informed decisions with regard to 
dosing and improve patient outcomes (Gage & Lesko, 2008). The eventual aim 
is to develop personalised drug therapies and progress is becoming more 
widespread following recently available genetic testing (French et al, 2010). 
Pharmacogenetics is the molecular basis that drives the processes of 
pharmacokinetics (the effect of the body on a drug) and pharmacodynamics 
(the effect of drugs on the body) (French et al, 2010). Fundamentally, it is the 
detection of single nucleotide polymorphisms (SNPs), in which the nucleotide 
sequence at a particular position is changed from the most common one (wild 
type) by substitution, deletion, insertion or translocation (Al-Ghoul & Valdes,
2008).
21
Table 1.2 Recommendations for the treatment of excessive 
anticoagulation
IN R  A c tio n
INR >3.0<6.0 (target 2.5) 
INR >4.0<6.0 (target 3.5)
Reduce warfarin dose or stop 
Restart when INR<5.0
INR >6.0<8.0 
Bleeding absent or minor
Stop warfarin 
Restart when INR<5.0
INR >8.0 
Bleeding absent or minor
Stop warfarin 
Restart when INR<5.0 
I f  risk factors for bleeding are 
present, administer 0.5-2.5mg 
vitamin K  orally
Major bleeding
Stop warfarin 
Give prothrombin complex 
concentrate (50U/kg)
Give 5mg vitamin K  (orally or i.v.)
BCSH 2006
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Several SNPs have been detected in recent years that appear to confer a 
greater sensitivity to warfarin and therefore such patients require a much lower 
daily dose than those exhibiting the wild-type gene (Elias and Topol, 2008).
1.6.1.1 Vitamin K epoxide reductase (VKOR) polymorphisms
The enzyme VKOR causes the reduction of vitamin K (see Fig 1.2), which is 
then responsible for the production of functionally active clotting factors II, VII, 
IX and X and it is this enzyme that is inhibited by warfarin (Reynolds et al, 
2007). Measurement of VKOR activity has been available since the 1970s, but it 
was not until 2004 that the gene, located on chromosome 16, was identified and 
designated VKORC1 (vitamin K epoxide reductase complex subunit 1) (Li et al, 
2004).
In recent years, several SNPs in VKORC1 have been shown to have a 
significant effect on warfarin dose requirements. However, complications have 
arisen in identifying which are responsible for warfarin sensitivity, due to the fact 
that the majority of VKORC1 SNPs are in linkage disequilibrium, i.e. they are 
located very close to one another on chromosome 16 and are therefore 
believed to be inherited together more often than would be expected by chance. 
Consequently, it is difficult to determine which individual SNP is responsible for 
the associated trait (Lindh, 2009). Further complications have occurred because 
several different notations have been used in the literature to designate the 
various VKORC1 polymorphisms (D’Andrea et al., 2005; Geisen at al., 2005; 
Reider et al., 2005) and these are shown in Table 1.3. Reider et al (2005) 
divided the VKORC1 SNPs into two main groups of jointly inherited 
polymorphisms, designated A and B, where group A is associated with a 
decrease in warfarin requirement and group B individuals show a requirement 
for higher warfarin doses. Geisen et al (2005) subdivided the VKORC1 variants 
into four groups, VKORC1 *1, *2, *3 and *4. VKORC1*1 is only found in African 
populations and VKORC1*2 is the equivalent of Reider’s group A and therefore 
confers warfarin sensitivity. Both VKORC1*3 and *4 relate to Reider’s group B 
and require much higher doses of warfarin to remain in the INR therapeutic 
range (Lindh, 2009). D’Andrea et al (2005) simply used the conventional 
nomenclature of the nucleotide change and its position.
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In order to maintain consistency, all further references in this thesis will refer to 
the VKORC1 polymorphisms using the D’Andrea notation.
1.6.1.2 VKORC1 polymorphisms in various populations
Many studies of VKORC1 polymorphisms and their effect on warfarin dosing 
have concentrated on non-Caucasian populations, especially Chinese and 
Japanese, whereas several North American groups have included Afro- 
Americans in their cohort (Yin & Miyata, 2007). Consequently, the results have 
shown a wide variation in SNPs, due to the genetic variations in the different 
ethnic groups. As the cohort for this present study does not include non- 
Caucasian warfarin patients (see Methods section 2.2.), the remainder of this 
section will give an overview of research performed on Caucasian subjects.
D’Andrea et al (2005) showed that in a group of male and female Southern 
Italians (n=147), the wild type (CC) of VKORC1 1173 C>T resulted in a mean 
optimum warfarin dose of 6.2mg/day, whereas two polymorphisms (CT and TT) 
reduced the dose significantly to 4.8mg/day (p=0.002) and 3.5mg/day (p<0.001) 
respectively. No other polymorphisms of VKORC1 showed any correlation to 
the warfarin dose. In a study of North Americans of southern German decent, 
Caldwell et al (2007), using a multiple regression model, showed that SNPs in 
VKORC1 1639 G>A resulted in a reduced warfarin dose requirement and made 
a significant contribution to predictive dosing when combined with the CYP2C9 
gene (see section 1.6.1.3), age, gender and body surface area (BSA).
Carlquist et al (2006), while studying 213 Swedish patients, found that VKORC1 
1173 C>T variants reduced the warfarin dose requirements by 65% (p<0.001) 
and that, together with CYP2C9, genetic testing explained 33% of dose 
variance, compared to 12% for clinical data alone. Similarly, Wadelius et al 
(2005) looked at three VKORC1 SNPs (1639 G>A, 1173 C>T and 2255 C>T) in 
201 Swedish subjects and showed that all had an effect on the maintenance 
dose required to keep the patients’ INR in the required therapeutic range. A 
study on British Caucasian patients was carried out by Sconce et al (2005), 
which showed that, in 297 subjects, the SNP in VKORC1 1639 G>A had a 
significant impact on dose requirements (p<0.001).
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Table 1.3 Nomenclature of the various VKORC1
polymorphisms (adapted from Lindh, 2009)
dbSNP Nucleotide
exchange
D’Andrea Reider 
A B
Geisen 
* !  *2 *4
rs9934438 C -*T 1173 C>T • •
rs9923231 G—»A 1639 G>A • •
rs8050894 G-^C 1542 G>C • •
rs2359612 C—>T 2255 C>T • •
rs7294 G—>A 3730 G>A • •
rs7200749 C-+T 3462 C>T • •
rs 17708472 C—>T 698 C>T • •
Nomenclature as described by D’Andrea et al (2005), Reider et al (2005) and 
Geisen et al (2005).
dbSNP = the Single Nucleotide Polymorphism Database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/)
Nucleotides: A=adenosine, C=cytosine, G=guanine, T=thymidine
1.6.1.3 C ytochrom e P450 (CYP) po lym orph ism s
Cytochrome P450 (CYP) enzymes are a group of haem proteins, found in 
hepatocytes, lung and kidney (Gardiner and Begg, 2006). One isoform,
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CYP2C9 located on chromosome 10, is responsible for the metabolism of 
weakly acidic compounds such as non-steroidal anti-inflammatory drugs, oral 
antidiabetics and S-warfarin (Lai et al, 2006). SNPs of the gene for CYP2C9 
were the first to be identified as having a significant effect on the therapeutic 
dose of warfarin (Scordo et al, 2002) and have been designated CYP2C9*2 and 
CYP2C9*3. Both are relatively common in Caucasians, with frequencies of 11- 
16% and 7-10% respectively (Lindh, 2009) and are responsible for amino acid 
substitutions in the CYP2C9 molecule (Arg144Cys with CYP2C9*2 and 
lle359Leu with CYP2C9*3). In each case, the altered molecule remains 
functional, but has a reduced S-warfarin clearance compared to the wild-type 
CYP2C9*1 (Lindh, 2009). S-warfarin clearance is lower by approximately 20% 
and 45% in heterozygotes for CYP2C9*2 and CYP2C9*3 respectively (*1/*2 
and *1/*3) when compared with the wild-type (*1/*1). In contrast, homozygotes 
for CYP2C9*3 (*3/*3) have a 90% reduced clearance of S-warfarin (Lindh,
2009). Therefore, CYP2C9*2 and CYP2C9*3 patients have an increased risk of 
over-anticoagulation, especially during the initiation stage, with a concomitant 
increase in the risk of haemorrhagic complications. Margaglione et al (2000) 
found that CYP2C9 variants were responsible for a 2.6 fold increase in the odds 
of bleeding when compared to the wild-type.
D’Andrea et al (2005) showed a significant influence of CYP2C9 polymorphisms 
on dosing in southern Italian Caucasians (n=147, r=0.215, p<0.001), while 
Carlquist et al (2006) found that the CYP2C9 variants reduced the required 
warfarin dose by 18-72% (n=213, p<0.001), when compared with the wild-type 
allele. Gage et al (2004) were only able to predict 10% of warfarin dose 
variability using CYP2C9 testing alone and emphasised the need to combine it 
with other clinical and pharmacogenetic data for each individual. Similarly, 
Sconce et al (2005), using a large group of 297 subjects, confirmed that the 
highest warfarin dose was required in those with the wild-type CYP2C9 gene 
and, together with VKORC1, age and height, was able to predict the correct 
therapeutic level in 55% of patients.
Kamali et al (2004) showed that CYP2C9 SNPs accounted for >20% of warfarin 
dose variability but suggested that measuring S- and R-warfarin concentrations 
in blood might be a more useful marker for identifying those patients with 
CYP2C9 variants, since the enzyme is only responsible for the elimination of S-
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warfarin. However, such a technique would be beyond the budget of most 
laboratories and investing in genetic testing would also allow the measurement 
of other polymorphisms such as VKORC1.
1.6.1.4 CYP4F2
Cytochrome 4F2 (CYP4F2) is a vitamin Ki oxidase (Fig 1.2) and therefore its 
mode of action may be the counterpart to that of VKORC1 in the vitamin K cycle 
(McDonald et al, 2009). A SNP of CYP4F2 (1347C>T) results in an amino acid 
substitution of valine for methionine at position 433 (Glurich et al, 2010), with 
the wild type being CC. It has been postulated that the presence of a T allele 
(CT or TT) causes a decrease in enzymatic activity, resulting in a reduced 
ability to metabolise vitamin Ki (McDonald et al, 2009) and therefore an 
increase in hepatic levels of the vitamin, as compared to the wild type CC. In 
the case of anticoagulated patients, this would require higher doses of warfarin 
in order to inhibit the vitamin K cycle and it has been suggested that CYP4F2 is 
responsible for 2-7% of warfarin dose requirements (Jonas and McLeod, 2009).
SNPs in CYP4F2 were first suggested as having an influence on warfarin dose 
requirements by Caldwell et al (2008). In the study, three independent cohorts 
of American Caucasian warfarin patients (total n=625) showed an increase of 4- 
12% in the required warfarin dose per T allele present (p=0.023), which 
translated to an increase of approximately 1 mg/day more in TT subjects when 
compared to the CC wild type.
The study also showed that, using clinical factors and data for the presence of 
VKORC1 and CYP2C9 SNPs, warfarin dose predictability from multiple 
regression analysis was 54%. However, this could be increased to 56% with the 
addition of CYP4F2 SNP data. The study concluded that, although the inclusion 
of CYP4F2 data had a significant effect on the ability to improve warfarin dose 
predictability, the potential benefits depended on race, as the frequency of the T 
allele decreased from 30% in Caucasians to 7% in African/Afro-Americans. 
Other studies have concluded that the homozygous TT allele of CYP4F2 has a 
significant effect on warfarin dosing. Pautas et al (2010), in a study of French 
Caucasians, demonstrated an actual but statistically insignificant increase in 
warfarin requirement (mg per day) due to the presence of the T allele for CC,
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CT and TT variants of 2.8±1.5, 3.0±1.5 and 3.3±1.7 respectively (n=300 
p=0.13). When CYP4F2 was added to the effect of other variables, the warfarin 
dose predictability increased by 1.4% (p=0.0545).
Carlquist et al (2010) in the USA, showed that CYP4F2 increased the 
predictability from 42% to 47% when added to a regression model (n=170 
p<0.001) and Sagrieya et al (2010), who also studied the effect of CYP4F2 in 
the USA, found that the gene added 4% to the variability of warfarin dosing 
(n=108 p<0.05). However, the ethnicity of the subjects in both studies was not 
stated. Wells et al (2010) also showed a significant increase in the daily warfarin 
dose in the presence of the TT allele, when compared to CC or CT (p<0.001) in 
a study of Canadian warfarin patients (n=249), in which 94% were Caucasian, 
but the actual value in mg per day was not stated.
Conversely, some studies have questioned the significance of CYP4F2 SNPs in 
warfarin dosing. Lubitz et al (2010) did not find any significant effect (n=145 
p=0.15) in the USA, but postulated that this could have been due to the 
inclusion of various ethnic groups in the study. Similarly, Kringen et al (2011), in 
a study of 105 Norwegian Caucasian patients, only found a weak association 
between warfarin dose and CYP4F2 (p=0.09) and concluded that the 
contribution of the gene was negligible. However, out of the seven subjects with 
the homozygous TT allele, four had various combinations of the CYP2C9*3 and 
the VKORC1 (1173 C>T) TT variant, which have both been shown to confer 
warfarin sensitivity (see Sections 1.6.1.2 and 1.6.1.3) and which may have had 
a counteractive effect on the results.
1.6.1.5 Other genetic variants affecting warfarin dosing
The enzyme y glutamyl carboxylase (GGCX) is an integral part of the vitamin K 
pathway and is responsible for catalysing the reaction between the vitamin and 
clotting factors II, VII, IX and X (Lai et al, 2006). In one study, Reider et al 
(2007) found that only one SNP of the gene showed a significant correlation 
with warfarin dose. However, this only accounted for 2% dose variance, as 
compared with VKORC1 (21%) and CYP2C9 (8%), suggesting that GGCX has 
little impact on warfarin dose studies.
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Apolipoprotein E (APOE) is involved in the hepatic uptake of lipid-soluble 
vitamin K (Lai et al, 2006) and the effect of this gene in warfarin dosing has only 
been studied by two groups. Sconce et al (2006) found only one variant of the 
APOE gene made a significant but small contribution to the daily warfarin dose 
(mean +/- SD) when compared to the wild type (3.3mg +/- 1.9 versus 4.0 +/- 
1.8, p=0.03). Using an algorithm of age + height + CYP2C9 + VKORC1 + 
APOE, they were able to make an accurate dosing prediction in 57% of 
patients, but concluded that APOE polymorphisms are not likely to be clinically 
significant in predicting dose requirements. A similar conclusion was made by 
Caldwell et al (2007), who found that APOE variants did not significantly 
contribute to a predictive dose model (n=570).
Genetic variants for the coagulation factors II, VII, IX and X have only been 
investigated in Japanese patients (Shikata et al, 2004). Homozygosity in one FI I 
gene and two FVII genes showed the lowest warfarin maintenance dose 
requirement (n=45, p<0.05) and it was suggested that genotyping for these 
three variants, together with CYP2C9, could be useful in predicting the warfarin 
response of an individual.
1.6.2 The influence of age on warfarin dosing
Several groups, when looking at factors affecting warfarin dose, have found a 
statistically significant, negative correlation with age and have shown close 
agreement, despite the wide variation in the number of patients studied. Kamali 
et al (2000b) showed that age accounted for 25% of maintenance dose 
variation (R2=0.25) and a later study equated this to a decrease of 
approximately 0.6mg of warfarin for each decade increase in age between 55- 
85 years old (Kamali et al, 2004).
This was confirmed by Sconce et al (2005), who showed a maintenance dose 
decrease of 0.5-0.7 mg per decade in patients between 20-90 years old, 
irrespective of their genotype or height. The largest of these studies (Gage et al, 
2004) showed that age contributed to an 8% decrease in dose for every decade 
(n=329). Garcia et al (2005) used weekly (as opposed to daily) dosing and 
estimated that increasing age was responsible for a decrease of 0.4 mg per 
week every year (95% confidence interval, Cl, 0.37-0.44, p<0.001). This was
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shown to have a marked effect in the initiation phase of therapy, if age was not 
taken into consideration. Using the loading regime of 5mg once daily for three 
days resulted in an overdose in 82% of females and 65% of males >70 years of 
age, leading to a significant risk of haemorrhage in the early stages of 
treatment.
Many physiological, as well as demographic and clinical factors, have been 
postulated to be responsible for the significant effect of age with respect to 
warfarin dosing. Liver size is known to decrease with age and it is possible that 
a smaller liver volume could cause a decrease in the metabolism of warfarin 
and therefore a reduced oral requirement (Wynne et al, 1995). However, there 
are other factors that may be responsible, either individually or in synergy. 
Increasing age has been shown to significantly contribute to the decreased 
plasma clearance of warfarin (Sconce et al, 2005), which could either be as a 
result of decreased liver volume, renal function or both. As the risk of thrombotic 
episodes, and therefore the likelihood of warfarin therapy, increases with age, 
the age distribution of patients on OAT is not normal but skewed. Furthermore, 
the elderly are more likely to have other interfering co-morbidities and therefore 
polypharmacy with drugs known to potentiate the effects of warfarin (see 
section 1.6.6) (Gurwitz et al, 1992). In addition, there is an increasing risk of 
malnutrition with increasing age and consequently a decreased intake of dietary 
vitamin K, leading to an increased anticoagulant response (Reynolds et al, 
2007).
1.6.3 The influence of gender on warfarin dosing
Kamali et al (2004) showed that gender had no significant effect on the warfarin 
dose in a cohort of British adults, and that the mean dose for females was 
3.49mg and males 3.98mg (p=0.59). However, the total number of subjects was 
relatively low (n=121) compared with other studies. Conversely, in a study by 
Garcia et al (2005) in the USA, which examined 4616 patients prospectively and 
7586 retrospectively, it was shown that females required 4.5mg per week less 
than men. On average, the maintenance dose of warfarin for men was 
30mg/week, whereas that for women was 25mg/week (p <0.0001) and the 
lowest doses were prescribed to women over the age of 80 years.
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The suggested explanation for this gender difference is that females, on the 
whole, have a smaller mean body size (measured as body surface area), which 
is directly related to liver size and therefore a lower hepatic fat content. This 
could lead to a reduced hepatic clearance of warfarin by cytochrome P450 
enzymes. However, data suggested that gender-related differences in warfarin 
dosing were independent of body weight. Alternatively, it has been suggested 
that some cytochrome P450 enzymes are regulated by sex steroids (Niemela et 
al, 1999). It appears that gender per se is not directly responsible for the 
difference in mean warfarin dose between men and women, but that it is due to 
the secondary effects of body and/or liver size and the metabolic effects of the 
cytochrome enzymes.
1.6.4 The influence of body size on warfarin dosing
Several groups have used some form of body size data in an attempt to 
ascertain whether or not this influences warfarin dose requirement. Only one 
group (Sconce et al, 2005) used height as a separate variable, showing that it 
significantly contributed to S-warfarin and total warfarin clearance (p=0.001). 
Using a multivariate regression model including height, age and two genetic 
variants (VKORC1 and CYP2C9) in 297 British patients, the estimated warfarin 
dose could be predicted in 55% of cases.
Using body weight as a variable, Carlquist et al (2006), in the USA, found it to 
be a weak parameter for optimum dose prediction (n=213 p=0.021), forecasting 
only 12% of patient doses when used together with age and gender as opposed 
to 33% when including CYP2C9 and VKORC1 genetic variants. Zhu et al 
(2007), also in the USA, increased the predictability to 61% when weight 
(p<0.0001), age (p=0.0003) and gender (p=0.0024) were considered with 
CYP2C9 and VKORC1 polymorphisms (n=65). A third study in the USA found 
that increasing weight inversely correlated with warfarin response and therefore 
required a lower dose (n=530 p<0.001) (Gurwitz et al, 1992).
Some studies have used a combination of weight and height by calculating the 
body surface area (BSA). Sconce et al (2005) found that BSA contributed 
significantly in a regression model for dose prediction (r=0.21, p=0.005). Gage 
et al (2004) showed that BSA had a 15% effect on warfarin dose (r=0.50,
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p<0.0001), suggesting that it correlates with liver size and therefore hepatic 
warfarin clearance. However, Kamali et al (2004) demonstrated that, although 
both body weight (r=0.25, p=0.005) and BSA (r=0.21, p=0.02) had an influence 
on warfarin dose, neither contributed significantly when used in a regression 
model. Reynolds et al (2007) stated that body size, however it is measured, is 
likely to account for much of the gender based differences in warfarin dose 
requirements, while Garcia et al (2005), in trying to reconcile the differences in 
significance, compromised by stating that patients whose weight deviates 
significantly from the norm for their age should have their body mass taken into 
consideration in any dosing decision.
1.6.5 The influence of vitamin K concentration on warfarin dosing
Kamali and colleagues in the UK have done much of the work regarding vitamin 
K levels and the effects on warfarin dosage. An initial study (Kamali et al,
2000a) showed a significant negative correlation between vitamin K
concentration and INR (r=-0.39, p=0.034) and it was suggested that the 
variability in dietary intake of the vitamin should be considered in patients with 
unstable warfarin control. Later in 2000, work by the same group (Kamali et al, 
2000b) showed a significant correlation between vitamin K levels and both 
warfarin dose (p=0.034) and its metabolite vitamin K epoxide (p<0.0001).
Further studies showed that there is a diurnal variation in vitamin K
concentrations, with a mean maximum at 22.00 hours and a mean minimum 
(68% reduction of the maximum) at 10.00hrs (Kamali et al, 2001). When used in 
a regression model, vitamin K levels made no significant contribution to the 
predicted warfarin dose (Kamali et al, 2004).
Although these findings have provided further insight into the factors affecting 
the response to warfarin, they offer no practical solutions in determining the 
optimum dosage for an individual, due in part to the expense and complexity of 
the assays, except perhaps in advising patients on the need for a well balanced 
diet during OAT.
1.6.6 The influence of drugs on warfarin dosing
Several drugs available today are known to affect warfarin dosage, by either 
attenuating or potentiating its mode of action (BCSH Guidelines, 1998). Some
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are prescribed for short-term use e.g. antibiotics, steroids etc. However, others 
are required for longer periods by anticoagulated patients, due to the fact that 
many suffer from co-morbidities, and include statins (for the reduction of 
cholesterol) and amiodarone (an anti-arrhythmic).
Simvastatin has been shown to reduce the daily warfarin dose requirement by 
approximately 9% (Hickmott et al, 2003; Sconce et al, 2006) and this is most 
likely due to its competition with warfarin in its metabolism through the P450 
enzymes, CYP3A4 and CYP2C9, which are responsible for the breakdown of 
R- and S-warfarin respectively. Voora et al (2005) created an algorithm in which 
the effect of simvastatin, fluvastatin and amiodarone were included, together 
with polymorphisms for CYP2C9, resulting in a 42% dose variance prediction. 
However, SNPs of the coagulation factors and VKORC1 were not tested for and 
it was suggested that inclusion of all these factors would improve the accuracy 
of future dosing algorithms.
Gurwitz et al (1992) constructed a multiple linear regression model using 
medication with either a potentiating (amiodarone, allopurinol and propranolol) 
or attenuating (corticosteroids and sucralfate) interactive effect with warfarin, on 
a cohort of 530 warfarin patients. The results showed that only the three drugs 
that increase the effect of warfarin had a significant effect on the predicted 
anticoagulant dose.
1.7 The use of mathematical algorithms in warfarin dosing
As stated previously (section 1.5.6), the initiation of warfarin therapy has 
traditionally been a matter of trial and error, with some studies attempting to 
develop dosing strategies based on clinical information and/or the dose given in 
the first few days of therapy (Crowther et al, 1999; Fennerty et al, 1984; Janes 
et al, 2004; Kovacs et al, 2003; Oates et al, 1998 and Tait and Sefcick (1997). 
However, in recent years, with the discovery that certain SNPs (see above) can 
have a significant effect on the variability of warfarin dosing between patients, 
several studies have attempted to construct mathematical algorithms for the 
prediction of an individual’s stable maintenance dose, based on a combination 
of demographic, clinical and pharmacogenetic information (Shaw et al, 2010).
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Many of these algorithms have been constructed using racially homogenous 
populations (Lubitz et al, 2010), such as Caucasians, African-Americans and 
southern or south-eastern Asians. Since the frequency of the two main SNPs 
(CYP2C9 and VKORC1) is significantly different between races (Yin and 
Miyata, 2007), studies which have attempted to compare the accuracy of the 
various algorithms have found it difficult without statistically sufficient numbers 
of all the ethnic groups.
The warfarin patients available for this study in the Anticoagulant out-patient 
clinic at Huddersfield Royal Infirmary (n=808) consisted of 95.5% Caucasian 
(n=772), 1.5% Afro-Caribbean (n=12), 2.6% southern Asian (n=21) and 0.4% 
south-eastern Asians (n=3). Since there were statistically insufficient numbers 
of non-Caucasians for this study, the published algorithms used for comparison 
were only selected if either they were constructed from a cohort of Caucasian- 
only subjects or if race could be removed without any detriment to the final 
result (Gage et al, 2004; Gage et al, 2008; IWPC. 2009; Sconce et al, 2005; 
Voora et al, 2005; Wadelius et al, 2009; Zambon et al, 2011 and Zhu et al, 
2007).
In addition to genetic factors, three of the studies mentioned above also 
calculated the efficacy of algorithms constructed of clinical and demographic 
data only (Gage et al, 2008; IWPC, 2009 and Zambon et al, 2011). Whereas 
most have used age and a measure of body size (height, weight, BMI or BSA), 
other parameters such as interacting drugs, target INR, smoking status and 
gender have been used less frequently. The various parameters used in the 
published algorithms chosen for testing in this study are shown in Table 1.4.
1.8 Aims and objectives of the study
It is clear that OAT is a vital treatment in the prevention and treatment of 
thromboembolism. However, finding the correct therapeutic dose for any 
individual patient is difficult, due to the numerous interacting clinical, 
demographic and genetic factors that influence warfarin and its action. 
Achieving a therapeutic INR quickly and safely in the initial stages of treatment 
is, at the present time, one of trial and error in the vast majority of cases.
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Consequently, any mechanism by which an individual’s therapeutic dose could 
be predicted with more accuracy should, as a consequence, help in both 
achieving a safe state of anticoagulation more quickly and maintaining it for 
longer. The hypothesis is that, by designing a more comprehensive algorithm 
than has been achieved in previous studies, the warfarin dose requirement can 
be predicted in a greater number of patients, which can be applied in the future 
for patients during the initiation stage of warfarin therapy. This will be achieved 
by the following objectives:
Objective 1.
To test and validate the DNA extraction methodology, fingerprick blood samples 
will be taken from a small number of healthy adult volunteers.
Objective 2.
Capillary blood samples will be taken from approximately 200 stable 
warfarinised patients, together with demographic and clinical data. After PCR 
analysis of the samples, to determine the SNPs of each individual, all the data 
collected from 160 of these patients will be used to design two comprehensive 
dosing algorithms, one based on clinical and demographic data alone and one 
which includes genetic polymorphisms. The data collected on the remaining 
patients will then be entered into the new algorithms, as well as into published 
algorithms, to determine which one can most accurately predict the known 
stable therapeutic warfarin dose in this cohort.
Objective 3.
Venous and capillary blood samples, together with clinical and demographic 
data will be collected from approximately 40 patients before they begin warfarin 
therapy. The venous samples will be used to assay the baseline coagulation 
factors II, VII, IX and X, as well as albumin levels. The albumin and factor assay 
data will be examined by linear regression, in order to determine whether any of 
the parameters are significant in determining the eventual therapeutic dose. If 
so, these data could be used to design a future algorithm, because many district 
general hospitals would find an accurate dosing algorithm useful, and many do 
not have the facilities for PCR analysis, but do have the capability to assay 
coagulation factors and albumin. Therefore, it is hoped that the genetic data
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may be substituted into the algorithm by albumin and coagulation factor levels 
and still maintain a high percentage of predictability, thereby producing a useful 
tool for many hospital anticoagulant departments in the UK.
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Chapter 2
Materials and methods 
2.1 Ethical approval
Ethical approval was obtained from the Leeds (Central) Research Ethics 
Committee for the National Research Ethics Service (Appendix I). Further 
approval was granted by the Research and Development Department, 
Calderdale & Huddersfield NHS Foundation Trust (Appendix II).
2.2 Subjects
Three separate groups of subjects were selected for the study; each group 
provided different information with regard to warfarin therapy that was ultimately 
used to produce the new dosing algorithms. Within each group, every subject 
was given a patient information sheet at least one week before their next clinic 
appointment and written consent was obtained prior to inclusion in the study. All 
subjects were Caucasian, due to the fact that previous studies have shown the 
absence of the selected SNPs in certain ethnic groups. In addition, less than 
10% of the patients attending the Anticoagulant Clinic at Huddersfield Royal 
(n=800) were non-Caucasian and consequently there were insufficient numbers 
to allow statistical analysis.
2.2.1 Group 1 - healthy controls
These consisted of healthy members of staff (n=12) from the Haematology 
Laboratory, Huddersfield Royal Infirmary.
2.2.2 Group 2 -  stable warfarin patients
These consisted of 207 individual patients, who regularly attended the out­
patient warfarin clinic at Huddersfield Royal Infirmary. The time interval between 
appointments varied, depending on the stability of their INR result. However, no 
patient was allowed to go more than 12 weeks between tests. Each patient had
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been taking warfarin for several months, if not years, and were only included in 
the study if both their INR was within the therapeutic range at the time of their 
visit and there had been no warfarin dose change for at least the previous 8 
weeks. Data from 160 of these patients were used to construct the algorithms 
for determining the most appropriate warfarin dose in future patients. The data 
of the remaining 47 patients were used to test the predictability of the 
constructed algorithms.
2.2.3 Group 3 -  pre-warfarin treatment patients
Patients were recruited to this group (n=20) after referral to the Anticoagulant 
out-patient clinic but before they had commenced warfarin therapy. Data from 
this group were used to determine the baseline levels of the vitamin K 
dependent coagulation factors (Fll, FVII, FIX and FX) and serum albumin. The 
stable warfarin dose was recorded, once the INR had reached the therapeutic 
range.
2.3 Blood samples
2.3.1 Group 1 subjects
A finger prick blood sample of approximately 100 pi was obtained and placed on 
an FTA® card (Whatman International Ltd.). This was used to optimise the DNA 
extraction procedure and the PCR methodology. Samples were randomly 
numbered from 1 to 12 and anonymized.
2.3.2 Group 2 subjects
As part of their routine clinic appointment, patients have a 50 pi finger prick 
blood sample taken, in order to measure their INR using a Thrombotrak 2® 
point-of-care testing machine (Axis-Shield Ltd). For the study, a further 100 pi of 
blood for DNA analysis was obtained from the same puncture site and this was 
applied to an FTA® card, which was then labelled with the patient’s unique 
hospital number for identification purposes.
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2.3.3 Group 3 subjects
Similarly, each group 3 subject had 100 pi of blood taken for DNA analysis. As 
is the case for all patients before the commencement of warfarin therapy, 
routine venous blood samples were taken for full blood count (FBC), liver 
function tests (LFTs), urea and electrolytes (U&Es) and a coagulation screen. 
Permission was obtained in the consent form to use any remaining plasma from 
these samples to assay albumin levels and the vitamin K dependent 
coagulation factors.
2.4 Demographic information
All the demographic information required for the patients on warfarin therapy 
was obtained from the DAWN AC anticoagulation software (4S Information 
Systems Ltd). This software package is used as a tool to enable the Biomedical 
Scientists at the Calderdale and Huddersfield NHS Foundation Trust 
Anticoagulant Service to determine the optimum warfarin dose and next test 
interval on each individual patient, following an INR test result.
From the database, the gender and age were obtained for each patient in 
groups 2 and 3. The height and weight of all patients in both groups were 
obtained by a health care assistant at their out-patient clinic visit at the time of 
blood sampling.
2.5 Clinical information
The following clinical data were also obtained from the DAWN AC software for 
all patients in group 2:
• Clinical indication for anticoagulant therapy
• Target INR
• Concomitant medications
• Stable warfarin dose
In the case of group 3 patients, the clinical indication for warfarin therapy, 
concomitant medications and target INR were all obtained from the patients’
referral form. The patients’ stable INR and warfarin dose were obtained from the
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DAWN AC database retrospectively, several weeks after the commencement of 
therapy.
2.6 DNA analysis
2.6.1 FTA® Elute cards
FTA® filter paper discs are designed for the collection and stabilisation of DNA 
from biological samples, prior to PCR analysis. They are impregnated with 
patented chemicals which both lyse cells to release the nucleic acids and also 
protect the DNA from microbial and fungal degradation. The blood samples are 
stable for several years, if stored in sealed pouches in a dry environment 
(www.whatman.com/FTAEIute.aspx#Orderinglnformation). Approximately 100 
pi of capillary whole blood was obtained from each subject in all three groups, 
which was applied to two separate areas on an FTA® card and allowed to dry at 
room temperature for over 2 hours. These were then stored in sealed plastic 
bags at room temperature, containing a desiccant packet.
Before the DNA extraction procedure, four 2mm sample discs were cut from 
each individual FTA® card, using a 2mm Harris Uni-Core device (Whatman 
International Ltd) and transferred to a pre-autoclaved 1.5ml PCR grade 
microcentrifuge tube (VWR International Ltd).
2.6.2 DNA extraction methods
Initial studies using the healthy control spots were performed to optimise the 
method for DNA extraction for subsequent PCR analysis.
2.6.2.1 QIAamp®DNA mini kit method (QIAGEN)
All the buffers provided by the manufacturer were proprietary with unknown 
chemical composition and concentration. Using the FTA® card samples from the 
group 1 subjects (n=12), 1 80jlxI buffer ATL was added to each microcentrifuge 
tube and incubated in a heating block at 85°C for 10 minutes.
After briefly centrifuging at room temperature and 6000g for 30 seconds, 20pl 
Proteinase K stock solution was added, the samples were vortexed and
incubated in a 56°C heating block for 60 minutes. Following a brief
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centrifugation as above, 200pl Buffer AL was added and, after immediate 
vortexing, the samples were incubated for a further 10 minutes at 70°C. The 
samples were again briefly centrifuged as above, before the addition of 200pl 
absolute ethanol and then vortexed thoroughly. Each sample was decanted by 
pouring into an individual Mini Spin Column, supplied in the kit, fitted to a 2ml 
tube and centrifuged at 6000g for 1 minute at room temperature. The filtrate 
was then discarded and 500pl Buffer AW1 added without wetting the rim of the 
column.
After a second centrifugation at 6000g for 1 minute, the filtrate was discarded 
and 500pl Buffer AW2 was added to the column. The samples were centrifuged 
at 20,000g for a further 3 minutes, the filtrate was discarded and the columns 
were re-centrifuged at 20,000g for 1 minute. The collection tubes were 
discarded, clean tubes attached to the columns and 150pl Buffer AE was added 
to each. These were incubated at room temperature for 1 minute before 
centrifugation at 6000g for a further minute. The columns were discarded, the 
DNA solution was then pipetted into a sterile Eppendorf tube, labelled and 
stored at -70°C. The DNA extracted from the samples was quantified using the 
Nanodrop® technique (section 2.6.2.2).
2.6.2.2 DNA quantification by NanoDrop®
All the samples of extracted DNA were quantified using a NanoDrop® ND-100 
Spectrophotometer (NanoDrop Technologies Inc., http://www.nanodrop.com). 
The absorbance at 260nm, using 1pl of each sample, gave the DNA 
concentration in ng/ml and the purity was determined from the ratio of the 
absorbance at 260nm to the absorbance at 280nm.
2.6.2.3 PCR analysis of the extracted DNA from the Group 1 subjects
A Taqman® allele probe for a common SNP unrelated to the study was used in 
order to assess the quality of the DNA, together with a Universal PCR Master 
Mix (Applied Biosystems Ltd.). The extracted DNA was analysed by PCR, in 
order to determine its integrity. The total reaction volume for each well of a 96- 
well Microamp™ optical plate was 10pl, consisting of 5pl Master Mix, 0.5pl 
probe and 4.5pl DNA (diluted in sterile pre-DEPC treated water) to a
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concentration of 10ng/4.5pl. A negative control was included in two wells of 
each run which, instead of DNA, consisted of 4.5|j| pre-DEPC treated water 
only. Each sample was run in duplicate.
2.6.2.4 QIAamp®DNA mini kit modified method (QIAGEN)
As poor results were obtained from the initial extraction method above (see 
results section 3.1), the following modifications to the protocol were made:
a) After the addition of Buffer AW2 and centrifugation, the tube and filter 
were cleaned thoroughly with a tissue.
b) Following the centrifugation at 20,000g, each filter was cleaned with a 
tissue after the collection tube had been discarded.
c) The final incubation with Buffer AE at room temperature was extended 
from 1 to 5 minutes.
The extracted DNA was again quantified using the Nanodrop® technique, as 
above.
2.6.2.5 Ethanol precipitation of haem
Due to the poor PCR results from section 2.6.2.2 (see results section 3.1), the 
extracted DNA samples were treated in order to remove any haem 
contamination derived from the original FTA® cards.
A 1/10 volume (4pl) of sodium acetate (3M, pH 5.2) and 120pl of 100% ethanol 
was added to 40pl of each extracted DNA sample in a 1.5ml microcentrifuge 
tube. These were incubated overnight at -20°C and centrifuged at >14,000x g 
for 30 minutes at room temperature. The supernatant was discarded, taking 
care not to lose the DNA pellet, which was then rinsed with 70% ethanol and 
centrifuged as before for 15 minutes. After discarding the supernatant, the DNA 
was resuspended in 60pl of sterile water for injection. The extracted DNA was 
again quantified using the Nanodrop®technique.
A total of five samples, covering a range of DNA concentrations (0.6-3.3ng/pl), 
were chosen for PCR analysis, as in section 2.6.2.2, with each sample being 
analysed in duplicate.
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2.6.2.6 Whatman® method for DNA extraction
Following poor results from the ethanol precipitation samples (see results 
section 3.1), a third DNA extraction method, as recommended by Whatman®, 
was performed. As only a small amount of sample remained from the group 1 
FTA® cards, discs were used from the first four group 2 subjects.
Four 2mm FTA® sample discs were each placed in a 1.5ml microcentrifuge 
tube, 500pl of sterile water for injection was added and pulse vortexed three 
times for a total of five seconds. Excess liquid was removed from the discs by 
gentle squeezing against the side of the tube with a sterile pipette tip, before 
transferring the disks to a clean, pre-autoclaved microcentrifuge tube containing 
75pl of sterile water for injection. All the tubes were transferred to a heating 
block at 95°C for 30 minutes, with pulse vortexing half way through the 
incubation. At the end of the incubation, each tube was pulse vortexed for 
approximately 60 times and briefly centrifuged for 30 seconds, in order to 
separate the discs from the eluate containing the eluted DNA. Using a sterile 
pipette tip, the discs were removed from each tube and the eluted DNA was 
measured by the Nanodrop® technique before storing at '20°C until analysis.
2.6.3 PCR methodology
2.6.3.1 General principles
The PCR methodology is based on the use of a thermostable DNA polymerase 
enzyme from the Thermophilus aquaticus bacterium (Taq), which amplifies DNA 
segments. The process occurs in three stages, with approximately 40-50 cycles 
at each stage:
1. Denaturation causes the hydrogen bonds between the double strands of 
DNA to be broken, forming two separate strands. This occurs at approximately 
95°C.
2. An annealing phase, at 55-65°C, allows two specific primers, or 
oligonucleotides, to match and bind to complementary sequences on the DNA 
strands, resulting in amplification of the region of interest. The primers are
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present in excess, compared to the DNA concentration, in order to maximise 
the chance of encountering the correct template.
3. The extension phase occurs at approximately 72°C, where the Taq 
polymerase adds a deoxynucleotide triphosphate (present in the reaction 
mixture) to an exact complementary match on the DNA template. This creates a 
DNA chain which complements the template.
2.6.3.2 Applied Biosystems TaqMan® Drug Metabolism Genotyping 
Assays
Each genotyping assay kit contains two specific TaqMan® probes 
(www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/general 
documents/cms_040597.pdf) each with a reporter dye at the 5’ end. The probe 
for allele 1 is linked to a VIC® reporter dye and the allele 2 probe to a FAM™ 
reporter dye. In addition, each probe is attached to a Minor Groove Binder 
(MGB) and a non-fluorescent quencher. The MGB allows the design of shorter 
probes by increasing the melting temperature for the specific probe length, 
while the quencher, at the 3’ end, allows detection of the reporter dye. In 
addition to the probes, each SNP assay requires TaqMan® Universal PCR 
Master Mix. This contains the DNA polymerase (AmpliTaq Gold®), the 
deoxynucleotide triphosphates and ROX™ Passive reference, an internal 
reference dye, which allows the signal from the reporter dye to be normalized, 
in order to correct for any internal fluctuations in the fluorescence. A graphic 
representation of the SNP assay is shown in Fig. 2.1.
2.6.3.3 Methodology for the SNPs VK0RC1, CYP2C9*2 and *3 & CYP4F2.
All samples from patient groups 2 and 3 were analysed for each of the four 
selected SNPs. In every run, each sample was assayed in duplicate in a 96-well 
MicroAmp™ Optical plate. The total reaction mixture for each well was 10pl, 
consisting of 5pl Master Mix, 0.5pl probe and 4.5pl DNA (diluted in sterile pre- 
DEPC treated water) to a final concentration of 10ng/4.5pl. A negative control 
was included in two wells of each run which, instead of DNA, consisted of 4.5pl 
pre-DEPC treated water. Each plate was covered with MicroAmp™ Optical 
Adhesive Film before placing in the Applied Biosystems’ StepOne™ Real-Time
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PCR Thermal Cycler and programming the recommended setting, as given in 
the assay data sheet (Table 2.1).
Table 2.1 Applied Biosystems PCR thermal cycler 
conditions
Times and temperatures
Initial step Denature Anneal/extend
Hold 50 cycles
10 min at 95°C 15 secs at 92°C 90 secs at 60°C
A 2 min HOLD step at 50°C was recommended prior to the initial 10 min at 95°C 
when using the TaqMan® Universal Master Mix.
2.6.3.4 Nucleotide sequences of the assay probes.
The nucleotide sequence of the forward primer with the SNP in square brackets 
were as follows:
CYP4F2
CCCCGCACCT CAGGGT CCGGCCACA[C/T]AGCT GGGTT GT GAT GGGTT CC 
GAAA
CYP2C9*2
GAT GGGGAAGAGGAGCATT GAGGAC[C/T]GT GTT CAAGAGGAAGCCCGCT 
GCCT
CYP2C9*3
TGTGGT GCACGAGGTCCAGAGATAC[C/A]TT GACCTT CTCCCCACCAGCCT 
GCC
VKORC1
GATTATAGGCGTGAGCCACCGCACC[G/A]GGCCAATGGTTGTTTTTCAGGT
CTT
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2.6.3.5 Reading and analysis of the plates
The StepOne™ software performed a genotype on the whole reaction plate 
simultaneously by plotting the fluorescent intensity of the reporter dyes from 
each well as an Allelic Discrimination Plot (Fig. 2.2) and assigned a genotype to 
each cluster of results according to their position. Fluorescence from the VIC® 
dye probe indicated the presence of allele 1 and allele 2 was denoted by 
fluorescence from the FAM™ dye. Heterozygosity for both alleles appeared as 
a diagonal cluster.
2.7. Coagulation factor assays
Citrated whole blood samples from group 3 subjects were centrifuged at 4000g 
for 8 minutes at room temperature. The plasma was aliquoted into screw 
capped polypropylene tubes, which were labelled with the patient’s hospital 
number and stored at -70°C within 2 hours of collection. Coagulation factors 
have previously been shown to be stable at this temperature for at least 18 
months (Woodhams et al, 2001). Assay of factors II, VII, IX and X were 
performed on an ACL TOP® analyser (Instrumentation Laboratory Ltd), using 
the vitamin K factor assay programme. The assays are based on the principle of 
turbidimetric clot detection. The coagulation end-point is determined by 
measuring the change in optical density of the samples during the reaction via 
transmitted light at 671 nm. The light absorption of the sample increases in 
proportion to the formation of a fibrin clot and consequently the decreasing 
transmittance through the sample is measured by a photo detector. The signal 
is then processed via computer software to determine the clot end-point. Before 
the analysis of the patients’ samples, a new calibration curve was constructed 
for each of the coagulation factors and all subsequent assay runs included a 
normal and a low control sample (HemosIL® normal control plasma and 
HemosIL® special test control level II).
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Fig. 2.2 Allelic discrimination plot
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Reproduced with kind permission from Applied Biosciences.
2.8 Albumin assay
Albumin levels on group 3 patients were performed in the Clinical Chemistry 
Department, Huddersfield Royal Infirmary, using a Randox Albumin 2 kit 
(Randox Laboratories Ltd.) and the Siemens Advia 2400 analyser (Siemens 
Healthcare Diagnostics, IL, USA). Briefly, the assay uses the indicator 5,5-
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dibromo-o-cresolsulphonphthalein (bromocresol purple, BCP), which binds 
quantitatively to serum albumin. The absorbance of the albumin-BCP complex 
is them measured using a spectrophotometer method at 600nm. The assay was 
calibrated using Randox Calibration serum Level 3 and controlled daily with 
Randox Assayed multisera levels 2 and 3. The method is linear up to 60.0 g/L 
and has a minimum detectable albumin concentration of 5.98g/L.
2.9 Statistical analysis
Statistical analyses were performed using MedCalc for Windows version 9.6.0.0 
(MedCalc Software, Mariakerke, Belgium). The Box and Whisker plots were 
produced using Microsoft® Excel Starter 2010 version 14.0.6112.5000 
(Microsoft Corporation). All data were tested for normality using the Kolmogorov 
Smirnov test and any which proved to be non-parametric were logarithmically 
transformed before analysis. The Pearson correlation coefficient was used to 
test the relationship between continuous variables and the warfarin dose; the 
means and standard deviations of the non-continuous parameters were 
analysed using the Student t-test. Comparisons between the means of 
continuous data was performed using the Analysis of Variance (ANOVA) and 
for non-continuous data by the Chi squared (x2) test. In all cases, a p value 
<0.05 was regarded as significant.
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Chapter 3 
Results
3.1 Demographic data
The demographic data is shown in Table 3.1. Only age and weight showed a 
non-parametric distribution, using the Kolmogorov Smirnov test, so these data 
were logarithmically transformed in order to calculate the means. Of the group 2 
subjects (n=207), 111 were male and 96 were female, with a mean age of 66.2 
years. The height (mean 1.69m) and weight (mean 85.8Kg) were used to 
calculate both the BSA (mean 2.00m2) and the BMI (mean 30.0 Kg/m2), using 
the following formulae:
BSA = Vfweiqht in Kg x height in m) (Mosteller, 1987)
36
BMI = weight (Kg) (World Health Organisation)
[Height (m)]2
The subjects were divided into two groups (based on the numerical order of 
their unique hospital number) consisting of an algorithm construction cohort 
(n=160) and an algorithm validation cohort (n=47). The analysis of variance 
(ANOVA) between the two groups showed no significant differences for age 
(p=0.815), height (p=0.116), weight (p=03821), BSA (p=0.671) and BMI 
(p=0.230). The pre-warfarinised patients (group 3, n=20) consisted of 15 males 
and 5 females, with an age range of 42-85 years (mean 68.6).
3.2 Clinical data
The clinical data, shown in Table 3.2, was taken from each subject’s entry on 
the DAWN 4S® dosing software and had been provided initially, at the start of 
the warfarin therapy, by the referral from the patient’s GP or consultant. The 
majority of all group 2 subjects (n=207) had a target INR of 2.5 (81.2%) and 
significantly less with a target of 3.0 or 3.5 (6.7% and 12.1% respectively). The 
commonest clinical indication for warfarin therapy was AF (51.2%), followed by 
DVT (17.4%), mechanical prosthetic heart valve (13.5%) and PE (9.7%). Other 
indications totalled 8.4%. Of the long term drugs which are known to interact.
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Table 3.1 Demographic data for all group 2 subjects, the construction cohort, 
the validation cohort and group 3 subjects.
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Group 3 
(n=20)
15(75.0)
5 (25.0)
o
Mean
67.8
1.76
91.1
IVZ
29.8
Range
42-85
1.56-1.88
62-110
1.63-2.37
24.9-37.5
ANOVA
a
0.815
0.116
0.821
0.671
0.230
U-i
mod
2.485
0.0512
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1.447
Group 2 validation 
cohort (n=47)
33 (70.2)
14(29.8)
7(14.9)
Mean
65.8
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82.8
2.01
28.9
Range
28-86
1.47-1.96
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20.1-41.9
Group 2 
construction cohort 
(n=160)
79 (49.4)
81 (50.6)
23 (14.4)
Mean
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83.6
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30.0
Range
23-90
1.47-1.89
42-233
1.33-3.45
17.9-68.8
All Group 2 
subjects 
(n=207)
111 (53.6)
96 (46.4)
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Mean
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2.00
odm
Range
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Group 3 
subjects 
(n=20)
5.3 (2.3-10.0)
IT)w▼■H
9 (45)O
19 (95)o
©
©
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©
©
2(10)©
sw
12 (60)
ANOVA
F=0.603 p=0.4.38
F=1.097
P=0.296
Chi squared
a
0.236
0.562
0.982
0.945
0.938
0.403
0.938
0.938
0.514
108*0
1 0.688680*0
0.677
0.312
1.402
0.337
0.001
0.005
900*0
0.699©©©©
900*0
0.427
0.063
0.161
2.917
0.173
1.020
Group 2 validation 
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72 (34.8)
20 (9.7)
28 (13.5)
24(11.6)
Mean warfarin dose, 
mg/day (range)
Target INR, n ( % ) :
2.5©
ITi
Clinical details, n
_ ( % ) :
AF
DVT
PE
Mechanical heart 
valve
Stent
Arterial thrombus
Arterial bypass
Aneurysm
TIA
Lupus
LVF
Drugs, n ( % )
Simvastatin
Amiodarone
Omeprazole
Aspirin
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with warfarin, 72 subjects (34.8%) were taking simvastatin, 28 (13.5%) 
omeprazole, 24 (11.6%) low dose aspirin and 20 (9.7%) amiodarone.
Using analysis of variance (ANOVA), there was no significant difference 
between the means of the construction cohort (n=160) and the validation cohort 
(n=47), with respect to the daily warfarin dose (F=0.603, p=0.4.8) and the target 
INR (F=1.097, p=0.296). The majority of subjects in both of these sub groups 
had a target INR of 2.5 (81.9% and 78.7% respectively). Comparison of the 
non-continuous data between the construction and validation cohorts was done 
using the Chi squared test (x2) and, in all the clinical details and interacting 
drugs, no significant differences were shown between the two groups.
The serum albumin and vitamin K dependent coagulation factors were assayed 
on all group 3 (pre-warfarinised) subjects (n=20) and all the parameters showed 
a normal distribution (Table 3.3).
Table 3.3 Albumin and coagulation factor levels for group 3 
subjects (n=20)
Mean ±SD Range
Albumin, g/L 39.9 2.8 34-45
F II, % 96.6 12.7 69-131
F VII, % 105.3 20.8 68-151
F IX, % 147.5 20.5 120-212
F X, % 104.3 12.3 75-125
3.3 DNA extraction
The DNA yield obtained by the different extraction methods is shown in Table 
3.4. The concentration, obtained from blood spots on the FTA® cards by the 
QIAamp mini kit (section 2.6.2.1), ranged from 6.2-12.4 ng/pl (mean=9.5 ng/pl, 
SD±1.71). The PCR analysis of the samples failed to produce any allelic 
discrimination using the common SNP assay (Fig 3.1). After implementing some 
modifications to the QIAamp method (section 2.6.2.3), the amount of DNA 
extracted was significantly lower than the original method, ranging from 2.0-6.9
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ng/pl (mean=3.6 ng/pl, SD±1.37). Consequently, PCR analysis of the samples 
was not performed. The samples were treated in order to remove any haem 
contamination and produced even lower amounts of DNA 
(range 0.4-3.3 ng/pl, mean=1.6 ng/pl, SD±0.82). PCR analysis of samples 4, 7, 
8, 9 and 11 (which were chosen as they covered a range of DNA 
concentrations) using the same SNP assay, did not show any allelic 
discrimination (Fig 3.2).Table 3.5 shows the DNA yield from a selection of group 
2 subjects (n=4), using the Whatman® extraction method (section 2.6.2.5). The 
amount of DNA obtained was significantly higher than with the previous 
methods (range 17.0-32.3 ng/pl, mean=21.3 ng/pl, SD 7.33). PCR analysis, 
using the VKORC1 SNP assay (Fig 3.3) showed good allelic discrimination in 
three samples. Subjects 2 and 3 were homozygous for each allele (GG and AA 
respectively) and sample 4 was heterozygous. Sample 1 was undetermined. 
Therefore, for future genotyping experiments, the Whatman® extraction method 
was used to extract the DNA from all the patient samples.
Table 3.4 DNA yields using various extraction methods
DNA (ng/pl)
Sample number QIAamp method Modified 
QIAamp method
After haem 
extraction
1 6.2 3.4 1.8
2 7.4 3.5 0.4
3 9.5 2.0 1.2
4 8.5 2.8 1.8
5 9.8 5.4 1.5
6 9.3 2.4 1.7
7 10.6 4.0 1.0
8 10.0 3.3 0.6
9 12.4 3.4 3.3
10 10.4 3.0 1.1
11 8.2 6.9 2.3
12 11.3 2.5 2.4
Mean 9.5 3.6 1.6
SD 1.71 1.37 0.82
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Table 3.5 DNA yields of selected group 2 subjects using the 
Whatman® extraction method
Sample number DNA (ng/pl
1 18.2
2 32.3
3 17.0
4 17.8
Mean 21.3
±SD 7.33
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Fig 3.1 Allelic discrimination plot of group 1 
subject DNA (n=12) using the QIAamp  
extraction method.
All samples were assayed singularly and the sample number is indicated by 
each allele plot.
Neg ctrl= negative control using water instead of DNA.
Allelic D iscrim ination Plot
123.1
.6
2.1
11
101.0
1.1
0.6
0.1
-0.4
N e g  C trl
-0.2 0.0 0.2 0.4 0.6 0.8-0.4
Allele 1
Legend
•  Homozygous Allele 1 /Allele 1 •  Homozygous Allele 2/Allele 2
•  Heterozygous Allele 1 /Allele 2 xUndeterm ined
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Fig 3.2 Allelic discrim ination plot of selected  
group 1 subjects DNA (n=5) following the precipitation 
of haem.
All samples were assayed in duplicate and the sample number is indicated by 
the side of each allele plot.
Neg ctr!= negative control using water instead of DNA.
Allelic Discrim ination Plot
0.055 X  7 X s
0.045
n eg  Ctrl
110.035
n eg  Ctrl
0.025
0.015
0.0050
-0.0050
11
0.048 0.053 0.058 0.063 0.068 0.073
Allele 1
Legend
•  Homozygous Allele 1 /Allele 1 m Homozygous Allele 2/Allele 2
•  Heterozygous Allele 1 /Allele 2 xUndeterm ined
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Fig 3.3 VK0RC1 SNP assay results of selected  
group 2 DNA samples (n=4) using the 
Whatman® extraction method.
All samples were assayed in duplicate and the sample number is indicated 
by the side of each allele plot.
Neg ctrl= negative control using water instead of DNA
Allelic Discrimination Plot
a 3V
* 3
4
A
22
m t
. i
yl
1
v J.
.—neg Ctrl
0.1 0.3 0.5 0.7 0.9
G
Legend
•  Homozygous Allele 1 /Allele 1 •  Homozygous Allele 2/Allele 2
•  Heterozygous Allele 1 /Allele 2 xUndetermined
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3.4 Pharmacogenetic data
The pharmacogenetic data for all groups of subjects is shown in Table 3.6. In 
the case of the VKORC1 polymorphisms, there were slightly more GA types 
(44.9%) compared to the wild-type GG (40.6%) in all group 2 subjects (n=207). 
For CYP2C9, the frequencies of the *2 and *3 alleles (*2/*2, *2/*3 and *3/*3) 
(5.8%) were much lower than either the homozygous wild-type (*1/*1) or 
heterozygous *1 alleles (*1/*2 and *1/*3) (94.2%). The majority of group 2 
subjects were homozygote wild-types for the CYP4F2 C allele (59.4%), with 
only 40.6% possessing one or two T alleles. There were no significant 
differences in the numbers of the three SNPs between the construction and 
validation cohorts, as demonstrated by the Chi squared test.
3.4.1 The variation of the warfarin dose within the various SNPs
Figure 3.4 shows the effect of each individual polymorphism on the stable 
warfarin dose, using data from the construction cohort (n=160). The median 
daily warfarin dose was 4.0mg in the CYP2C9 homozygous wild type (*1/*1), 
which was the same as in the *1/*2 genotype. However, this was significantly 
higher than found in *1/*3 (2.7mg), *21*2 (2.0mg), *2/*3 (1.0mg) and *3/*3 
(0.5mg). The median daily dose was 5.3mg in the VKORC1 wild type (GG), 
which was higher than that found in the GA (3.5mg) and AA (2.3mg) genotypes. 
The wild type CYP4F2 (CC) had a median dose of 3.5mg/day, which increased 
in the presence of the T allele (CT 4.0mg and TT 5.5mg).
3.4.2 The effect of the number of SNPs on the warfarin dose
Using the data from all the group 2 subjects (n=207) in order to obtain a 
significant number of allele combinations, each subject was categorised 
depending on the number of polymorphisms they possessed (Figure 3.5). 
Those who exhibited only the wild type for each of the three genes (VKORC1 
GG, CYP2C9 *1/*1 and CYP4F2 CC) had a median daily warfarin dose of 
5.8mg. An increase in the number of SNPs present (1, 2 or 3) showed a 
corresponding decrease in the median dose (3.7mg, 3.5mg and 3.0mg 
respectively), despite the possible presence of a CYP4F2 SNP which has the 
effect of increasing the warfarin dose.
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Group 3 subjects 
(n=20)
9 (45.0)
(0'0S)0l
Sd
15(75.0)
3(15.0)
2(10.0)
0(0)
0(0)
0(0)
S'©oo
9 (45.0)
3(15.0)
Chi squared
____ _______________ _______ _________  _ _ _ .Q<
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0.598
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0.451
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3.5 Construction of the clinical/demographic algorithm
Using the data from the construction cohort (n=160), correlation analysis was 
performed between each continuous variable (age, weight, height, BSA and 
BMI) and the stable warfarin dose (Table 3.7 a). Since age and weight were 
shown to be non-parametric, using the Kolmogorov Smirnov test, these data 
were logarithmically transformed. For each of the non-continuous variables 
(gender, smoking status and the interacting drugs), a Student-t test was 
performed to compare the means and SDs of the stable warfarin dose, 
depending on whether the variable was present or absent, i.e. smoker and non- 
smoker, male and female etc. These data are shown in Table 3.7 b. There was 
a strong correlation between age and the warfarin dose (p<0.001). Similarly 
height, weight, BMI and BSA showed significant correlations; however, this 
would be expected as height and weight are functions of the BSA and BMI. For 
the non-continuous variables, gender (p=0.020), smoking status (p=0.018) 
amiodarone use (p=0.012), AF (p<0.0001) and DVT (p=0.030) appeared to 
have a significant effect on the stable warfarin dose.
3.5.1 Simple regression analysis of the clinical and demographic variables
As the published algorithms use either the square root (V) or log of the warfarin 
dose (see Appendix XI), these data in the construction cohort were tested using 
Kolmogorov Smirnov analysis, to determine which transformation produced the 
best indication of normality. Raw warfarin dose data was rejected as having a 
normal distribution (p=0.036), but both the log and square root of the data were 
shown to be parametric (p=0.256 and p=0.544 respectively). It was therefore 
decided that, in the following regression analyses and the final algorithms, the 
square root of the warfarin dose would be used, due to it having a higher p 
value.
3.5.1.1 Simple regression analysis of the continuous clinical and 
demographic variables versus actual warfarin dose
In order to determine if the continuous variables would require transformation in
the final algorithms, regression analyses were performed between the Vdose
and either the raw data, the V data or the log data (Table 3.8).
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Table 3.7a Correlation coefficients (r) between the actual 
warfarin dose and the continuous demographic and clinical 
variables for the construction cohort (n=160).
Significant p value <0.05
r P
Age -0.4953 <0.0001
Weight 0.3097 0.0001
Height 0.3136 <0.0001
BSA 0.3407 <0.0001
BMI 0.2123 0.0070
Table 3.7b Student t-test for the stable warfarin dose versus the 
presence or absence of the non-continuous clinical and 
demographic variables in the construction cohort (n=160).
Significant p value <0.05
t statistic P
Male -2.344 0.020
Female 2.344 0.020
Smoking status -2.386 0.018
Simvastatin 1.774 0.078
Amiodarone 2.555 0.012
Omeprazole 1.377 0.171
Aspirin 0.361 0.719
AF 4.541 <0.0001
DVT 2.188 0.030
PE 0.719 0.473
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Table 3.8 Regression analysis of the actual warfarin dose 
versus the continuous clinical and demographic variables
a) Vdose vs. variable
b) Vdose vs. ^variable
c) Vdose vs. log variable
p values significant if <0.05
a
R* F ratio P
Age 0.236 48.898 <0.001
Weight 0.100 17.588 <0.001
Height 0.069 11.688 0.001
BSA 0.120 21.505 <0.001
BMI 0.049 8.111 0.005
b
R* F ratio P
VAge 0.229 46.907 <0.001
VWeight 0.106 18.734 <0.001
^Height 0.069 11.738 0.001
VBSA 0.121 21.708 <0.001
VBMI 0.050 8.370 0.004
c
R* F ratio P
log Age 0.218 43.991 <0.001
log Weight 0.107 18.998 <0.001
log Height 0.069 11.783 0.001
log BSA 0.120 21.612 <0.001
log BMI 0.051 8.511 0.004
All the variables had similar R2, F ratio and p values, irrespective of the 
transformation method, when compared to the raw data. It was therefore
decided, for simplicity, to use the raw data in the multiple regression analysis.
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3.5.1.2 Simple regression analysis of the non-continuous clinical and 
demographic variables versus actual warfarin dose
As the non-continuous variables (smoking status, gender, clinical indication for 
warfarin therapy and use of interacting drugs) could not be transformed, simple 
regression analysis was performed on these data (Table 3.9), in order to 
confirm the results of the Student t-test (Table 3.6b).
Table 3.9 Sim ple regression analysis for the actual warfarin  
dose versus the non-continuous clinical and dem ographic  
variables in the construction cohort (n=160).
Significant p value <0.05
R F ratio P
Smoking status 0.028 4.579 0.034
Simvastatin 0.012 1.984 0.161
Amiodarone 0.039 6.414 0.012
Omeprazole 0.013 2.081 0.151
Aspirin 0.001 0.087 0.769
Male 0.027 4.321 0.039
Female 0.027 4.321 0.039
AF 0.124 22.342 <0.001
PE 0.004 0.626 0.430
DVT 0.027 4.398 0.038
The results showed that the variables with a significant effect on the warfarin 
dose were smoking status (p=0.0.34), amiodarone use (p=0.012), gender 
(p=0.039), AF (p<0.001) and DVT (p=0.038), confirming the results of the 
Student t-test.
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3.5.1.3 Simple regression analysis of the target INR versus actual warfarin 
dose
Although the target INR is a non-continuous variable, there are three possible 
values i.e. 2.5, 3.0 and 3.5. In order to perform the regression analysis, these 
data were converted into the dummy variables Zi and Z2:
Target INR 2.5 3.0 3.5
Z1 1 0 0
Z2 0 1 0
Using these dummy variables in a regression analysis, the target INR showed a 
significant effect on the warfarin dose (F ratio 16.975, p<0.001) and therefore it 
was included in the final algorithms.
3.5.1.4 Multiple regression analysis of the significant clinical and 
demographic variables
The multiple regression analysis, for the construction of the algorithms may be 
performed either forwards or backwards, with the possibility of different results 
by the two methods. Therefore, the clinical data, which had previously been 
shown to have a significant effect on the warfarin dose, was entered into the 
multiple regression calculation by both methods (Table 3.10).
There was no difference in the outcome of the results when using either the 
forward or backward regression. The same variables (age, BSA, smoking 
status, amiodarone use and target INR) were included in both methods and 
showed exactly the same co-efficient and p values. Both methods removed 
weight, height, BMI, gender, AF and DVT from the regression model. 
Consequently, the final clinical/demographic algorithm was constructed using a 
forward multiple regression model.
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Table 3.10 Multiple regression analysis of the actual warfarin  
dose versus the significant clinical and demographic data, by 
the a) forward and b) backward methods, for the construction  
cohort (n=160).
Significant p value <0.05
a)
Dependent Y Vwarfarin dose
Method Forward
Enter variable if P< 0.05
Remove variable if P> 0.1
Sample size 160
Coefficient of determination R2 0.3595
Readjusted 0.3387
Multiple correlation coefficient 0.5996
Residual standard deviation 0.4061
Regression Equation
Independent variables Coefficient Std. Error t P
(Constant) 1.3139
age -0.01239 0.002627 -4.718 <0.0001
BSA 0.4058 0.1235 3.285 0.0013
smoking status 0.2073 0.09332 2.222 0.0278
amiodarone -0.3187 0.1030 -3.096 0.0023
target INR 0.2602 0.09412 2.765 0.0064
F-Ratio 17.2855
Significance level P0.001
b)
Dependent Y 
Method
Enter variable if P< 
Remove variable if P>
Vwarfarin dose
Backward
0.05
0.1
Sample size
Coefficient of determination R2 
Readjusted
Multiple correlation coefficient 
Residual standard deviation
160
0.3595
0.3387
0.5996
0.4061
Independent variables Coefficient Std. Error -... . - ' - Vt P
(Constant) 1.3139
age -0.01239 0.002627 -4.718 <0.0001
BSA 0.4058 0.1235 3.285 0.0013
smoking status 0.2073 0.09332 2.222 0.0278
amiodarone -0.3187 O'1030 -3.096 0.0023
target INR 0.2602 0.09412 2.765 0.0064
F-Ratio 17.2855
Significance level P<0.001
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3.5.1.5 The clinical/demographic algorithm
Using the data from the forward multiple regression analysis of the significant 
clinical and demographic data (Table 3.10a), the following algorithm was 
constructed:
Warfarin dose = [1.3139 - (0.01239 x age) + (0.4058 x BSA)
(mg/day) + (0.2073 x smokes) - (0.03187 x amiodarone)
+ (0.2602 x target INR)]2
where: age (in years) and BSA (in m2)
smokes = 1 for a smoker and 0 for a non-smoker 
amiodarone = 1 (present) or 0 (absent)
3.6 Simple regression analysis of the genetic polymorphisms versus 
the actual warfarin dose
A simple regression calculation was performed on each of the polymorphisms 
(Table 3.11). The results showed that four of the twelve SNPs had no significant 
effect on the Vwarfarin dose, CYP2C9 *1/*2 (p=0.862), VKORC1 GA (p=0.346), 
CYP4F2 CT (p=0.205) and CYP4F2 TT (p=0.053). From the Box and Whisker 
plot of the various SNPs (Figure 3.4), the median warfarin dose for CYP *M*2 
was the same as for the wild-type *1/*1; however, the other three 
polymorphisms did display a visible difference in the median dose as compared 
to the wild-type. Following this discrepancy, it was decided to include all the 
SNPs in a multiple regression analysis.
3.6.1. Multiple regression analysis of the genetic polymorphisms versus 
the actual warfarin dose
A multiple regression analysis, both forwards and backwards, was performed on 
all the polymorphism data against the square root of the warfarin dose, without 
the clinical or demographic variables, but no results could be calculated. The 
process was repeated without inputting the wild-type genes (CYP2C9 *1/*1, 
VKORC1 GG and CYP4F2 CC). The results are shown in Table 3.12.
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The forward regression model removed the CYP4F2 CT and TT SNPs and 
produced an adjusted R2 of 0.3582 (F ratio 13.675, p<0.001). Using the 
backward regression produced a higher adjusted R2 of 0.3686 but a lower F 
ratio of 12.6008 (p<0.001). This method also included CYP4F2 TT, but with a 
high p value of 0.0631. Based on these data, it was decided to use the forward 
regression method for the final calculation of the pharmacogenetic algorithm, 
based on the higher F ratio.
Table 3.11 Simple regression analysis for the actual warfarin  
dose versus the SNPs in the construction cohort (n=160).
Significant p value <0.05
SNP R2 F ratio P
CYP *1/*1 0.0662 10.776 0.001
CYP *1/*2 0.0002 0.030 0.862
CYP *1/*3 0.0378 6.213 0.014
CYP *21*2 0.0270 4.390 0.038
CYP *2 I*Z 0.0675 11.437 0.001
CYP *3/*3 0.0419 6.912 0.009
VKORC1 GG 0.1211 21.778 <0.001
VKORC1 GA 0.0056 0.593 0.346
VKORC1 AA 0.1494 22.761 <0.001
CYP4F2 CC 0.0310 5.046 0.026
CYP4F2 CT 0.0101 1.618 0.205
CYP4F2 TT 0.0235 3.804 0.053
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Table 3.12 Multiple regression analysis of the actual warfarin  
dose versus the SNPs in the construction cohort (n=160) by a) 
forward and b) backward methods.
Significant p value <0.05
a)
Dependent Y Vwarfarin dose
Method Forward
Enter variable if P< 0.05
Remove variable if P> 0.1
Sample size 160
Coefficient of determination R2 0.3864
Readjusted 0.3582
Regression Equation
Independent variables Coefficient Std. Error t P
I (Constant) 2.3100
VKORC1 GA -0.2336 0.06922 -3.374 0.0009
VKORC1 AA -0.6978 0.1023 -6.818 <0.0001
CYP2C9 *1/*2 -0.1968 0.08055 -2.444 0.0157
CYP2C9 *1/*3 -0.5586 0.1399 -3.993 0.0001
CYP2C9 *21*2 -0.5866 0.1845 -3.179 0.0018
CYP2C9 *21*2 -0.9429 0.2347 -4.017 0.0001
CYP2C9 *3/*3 -0.9051 0.4098 -2.209 0.0287
Variables not included in the model
CYP4F2 CT
CYP4F2 TT
F-Ratio 13.6750
Significance level P<0.001
b)
Dependent Y Vwarfarin dose
Method Backward
Enter variable if P< 0.05
Remove variable if P> 0.1
Sample size 160
Coefficient of determination R2 0.4003
Readjusted 0.3686
Regression Equation
Coefficient Std. Error t P
(Constant) 2.2811
VKORC1 GA -0.2109 0.06972 -3.026 0.0029
VKORC1 AA -0.7046 0.1016 -6.937 <0.0001
CYP2C9 *M*2 -0.1909 0.07996 -2.387 0.0182
CYP2C9 *1/*3 -0.5448 0.1390 -3.920 0.0001
CYP2C9 *21*2 -0.5757 0.1831 -3.145 0.0020
CYP2C9 *2/*3 -0.9193 0.2331 -3.943 0.0001
CYP2C9 *3/*3 -0.8694 0.4069 -2.137 0.0342
CYP4F2 TT 0.2382 0.1273 1.872 0.0631
Variables not included in the model
CYP4F2 CT
F-Ratio 12.6008
Significance level P<0.001
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3.6.2 Multiple regression analysis of all the relevant clinical, demographic 
and genetic data versus the actual warfarin dose.
Using the clinical and demographic data from 3.5.1.5 and the genetic data from
3.6.1, a forward multiple regression analysis was performed (Table 3.13). This 
gave an adjusted R2 value of 0.6268 (F ratio 23.250, p<0.001). CYP4F2 CT was 
removed from the model, together with smoking status, which had the highest p 
value (p=0.0278) in the clinical regression model.
From these data (Table 3.13) the following pharmacogenetic algorithm was 
produced:
Warfarin dose = [1.9708 - (0.01145 x age) + (0.3119 x BSA)
(mg/day) - (0.3766 x amiodarone) + (0.1768 x target INR)
- (0.6863 x VKORC1 AA) - (0.2136 x VKORC1 GA)
- (0.1957 x CYP2C9 *1/*2) - (0.435 x CYP2C9 *1/*3)
- (0.3524 x CYP2C9 *21*2) - (0.8539 x CYP2C9 *2/*3)
- (0.6471 x CYP2C9 *3/*3) + (0.228 x CYP4F2 TT)]2
where: age (in years) and BSA (in m2)
amiodarone = 1 (present) or 0 (absent)
SNPs = 1 (present) or 0 (absent)
3.7 Correlation and simple regression analyses of the albumin and factor 
assay data from the group 3 subjects (n=20) versus the actual warfarin 
dose.
The pre-warfarin levels of albumin and factors II, VII and X showed no 
correlation with the warfarin dose (Table 3.14). However, there was an inverse 
correlation between the warfarin dose and factor IX (r=-0.6078, p=0.005). These 
data were confirmed using a simple regression analysis (Table 3.15), in which 
factor IX had an R2 value of 0.3694 (F ratio=10.545, p=0.004).
Factor IX was the only parameter accepted by a forward multiple regression 
model, giving an adjusted R2 of 0.3342 (co-efficient = -0.0139 p=0.005, F ratio = 
10.539 p = 0.004).
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Table 3.13 Forward multiple regression analysis of the actual 
warfarin dose versus the clinical, demographic and genetic 
data in the construction cohort (n=160).
Significant p value <0.05
Dependent Y Vwarfarin dose
Method Forward
Enter variable if P< 0.05
Remove variable if P> 0.1
Sample size 160
Coefficient of determination R2 0.6549
Readjusted 0.6268
Multiple correlation coefficient 0.8093
Residual standard deviation 0.3051
Regression Equation
Independent variables Coefficient Std. Error « P
(Constant) 1.9708
CYP2C9 *1/*2 -0.1957 0.06183 -3.165 0.0019
CYP2C9 *17*3 -0.4350 0.1077 -4.037 0.0001
CYP2C9 *21*2 -0.3524.... ...... ....... ...... 0.1429 -2.466 0.0148
CYP2C9 *21*3 -0.8539 0.1804 -4.732 <0.0001
CYP2C9 *3/*3 -a6471 0.3140 -2.061 0.0411
VKORC1 AG -0.2136 0.05467 -3.907 0.0001
VKORC1 AA -0.6863 0.07892 -8.696 <0.0001
CYP4F2 TT 0.2280 0.09833 2.318 0.0218
Age -0.01145 0.0020 -5.723 <0.0001
BSA 0.3119 0.09398 3.319 0.0011
Amiodarone -0.3766 0.07718 -4.880 <0.0001
Target INR 0.1768 0.07281 2.428 0.0164
F-Ratio 23.2500
Significance level P<0.001
Variables not included in the model
CT
Smoking status
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Table 3.14 Correlation of the actual warfarin dose versus  
albumin and coagulation factors in the group 3 subjects (n=20).
Significant p value <0.05
r P
Albumin -0.3408 0.142
F II 0.1330 0.576
F VII -0.0072 0.976
FIX -0.6078 0.005
FX -0.3802 0.098
Table 3.15 Simple regression analysis of the actual warfarin  
dose versus albumin and coagulation factors in the group 3 
subjects (n=20).
Significant p value <0.05
R2 F ratio P
Albumin 0.1161 2.365 0.141
F II 0.0177 0.324 0.576
F VII 0.0001 0.001 0.976
FIX 0.3694 10.545 0.004
FX 0.1445 3.041 0.098
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Chapter 4
Discussion
There is little doubt that the use of warfarin, both therapeutically and 
prophylactically, has made a major impact on the treatment of thromboembolic 
disease in the last sixty years or so and countless millions of lives have been 
saved worldwide during this time. However, the dosing of warfarin is unlike the 
majority of drug therapies available to clinicians, in so far as there is no linear 
titration between the dose and its pharmacological effect. In addition, the 
consequences of under or over estimating the dose in any given patient can 
have serious outcomes with regard to morbidity and mortality.
It is with these facts in mind that several groups have attempted to formalise a 
dosing schedule based on frequent, often daily INR testing (Fennerty et al, 
1984; Tait and Sefcick, 1997). These studies have been shown to reduce the 
time taken for the INR to become therapeutic at initiation, as well as reducing 
the number of adverse events when compared to the usual trial and error 
approach used by many anticoagulant centres. However, with the emergence of 
pharmacogenetics and the discovery of SNPs which have been shown to have 
a significant influence on the stable warfarin dose, other studies have attempted 
to create a dosing regimen from a mathematical algorithm, by combining 
different combinations of clinical, demographic and genetic factors (Zambon et 
al, 2011; Sconce et al, 2005; D’Andrea et al, 2005).
It was the aim of this study to create two new algorithms using as many 
variables as possible, all of which had previously been shown to have a 
significant effect on the stable warfarin dose. The first algorithm was composed 
of clinical and demographic data obtained from a cohort of stable 
anticoagulated patients, in order to show that it is possible to improve the 
accuracy of warfarin dosing at the beginning of the treatment. If successful in 
practice, this would lead to a reduction in the number of adverse events, as well 
as attaining the therapeutic INR range more quickly, in centres which do not 
have the facilities for DNA analysis.
The second algorithm consisted of the same clinical and demographic data, but 
also included genotype data on four SNPs which have been shown to have a
significant effect on the pharmacokinetics and pharmacodynamics of warfarin 
therapy (see section 1.6.1). By combining all these parameters, it was the 
intention to improve the predictability of warfarin dosing beyond that of 
previously published algorithms, since many of these used only a selection of 
demographic, clinical and genetic parameters.
4.1 The demographic and clinical data
From the total number of warfarin patients available for the study (n=808), not 
all were invited to take part. During the time of recruitment, many had 
completed their course of therapy and were therefore discharged from the 
outpatient clinic before they could be asked to participate. In addition, some 
patients refused (n=25), while others were unsuitable according to the Leeds 
(Central) Research Ethics Committee criteria, due to varying degrees of 
dementia.
Further limitations on the number of patients available for the study came from 
the fact that all subjects were required, at the time of recruitment, to have an 
INR within the therapeutic range for at least the previous eight weeks. 
Inevitably, some subjects did not fulfil this criterion during the course of the 
study. In addition, a decision was made during the design of the study to only 
include Caucasian subjects. This was primarily done due to the fact that there 
were statistically insufficient numbers of non-Caucasians available (see 1.7). In 
addition, it has been shown that some SNPs which have an effect on the stable 
warfarin dose are more prevalent in non-Caucasians (see 1.6.1.1) and it was 
not financially possible to include all of these in the study, even if the numbers 
of non-Caucasians had been higher. In trying to produce an algorithm without 
these SNPs but including non-Caucasians in the cohort would have meant 
skewing the final results and therefore decreasing the efficacy of the algorithm 
produced.
With this in mind, published algorithms were chosen for comparison with the 
one constructed in this study only if they were created either using Caucasian- 
only data or a racially heterogeneous group but which allowed for Caucasian 
subjects to be entered into the final algorithm without any detriment to its 
predictability.
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4.1.1 Demographic factors
In the final regression analysis, age was shown to be a significant factor in 
determining the stable warfarin dose (p>0.0001), confirming the findings of 
many other studies and which was included in all the chosen algorithms. 
However, although there was a significant correlation between the stable 
warfarin dose and gender (p=0.020) (see section 3.5), in the final multiple 
regression analysis it was removed by the Medcalc software. A possible 
explanation is that, as females generally tend to have a smaller body mass than 
males, the combination of height, weight, BMI and BSA into the model was 
sufficient to override the influence of gender. In addition, the correlation 
coefficients for height and BSA (Table 3.7a) were more highly significant 
(p<0.0001) than those for weight and BMI (p=0.0001 and p=0.007 respectively), 
suggesting that the latter were removed in the multiple regression. The eight 
published algorithms chosen for comparison with this study all use various 
combinations of gender and/or body mass, so it appears to suggest that, as 
stated in section 1.6.3, the relationship between the stable warfarin dose and 
gender is not a direct one but multifactorial and that some provision of either 
gender or body mass in an algorithm would be an overarching parameter for 
this particular aspect of warfarin dosing. Furthermore, to include a measure of 
body mass instead of gender in an algorithm would negate the problem of 
reducing the warfarin dose for large females or increasing it for small males.
4.1.2 Interacting drugs
The number of drugs which have an effect on an individual’s stable warfarin 
dose is extensive and it would not have been possible to investigate them all in 
this study. Those which were chosen are the most commonly encountered long 
term drugs used by patients attending the Huddersfield Royal Infirmary 
anticoagulant clinic and, although drugs such as antibiotics can also 
significantly affect warfarin in the short term and therefore require closer I NR 
monitoring at the time, amiodarone, simvastatin and aspirin may cause a 
permanent reduction in the warfarin dose (Holbrook et a/, 2005). In the chosen 
published algorithms, which included interacting drugs, three found amiodarone 
and statins to have a significant influence (Gage et al, 2004; Gage et a/, 2008; 
Voora et al, 2005) and one found amiodarone alone to have a significant
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influence (IWPC, 2009). Interestingly, the two studies by Gage et al (2004 & 
2008) also found prophylactic aspirin to have a significant effect, but the patient 
cohorts were much larger than this study (n=329, n=1015 respectively). In this 
study, 13.1% of patients in the construction cohort were taking aspirin (n=21), 
but this proved not to be significant in the simple regression analysis R2=0.001, 
p=0.769, see Table 3.9)
In this study, although simvastatin was the commonest drug among the 
construction cohort (33.8%), only amiodarone, taken by 11.9%, was found to 
have a statistically significant influence on the stable warfarin dose and was 
included in the final algorithm. This reinforces our current practice in which 
patients taking amiodarone are initiated on a lower warfarin dose than those 
who are not, or are monitored more frequently if starting amiodarone while 
already on warfarin.
4.1.3 Clinical parameters
Simple regression analysis for the clinical indications of warfarin therapy (Table 
3.9) showed a significant relationship between AF (p<0.001) and DVT (p<0.038) 
and the warfarin dose, but not for PE (p=0.430). However, in the construction of 
the algorithm, the clinical indications for OAT were removed. It is difficult to 
justify how the clinical condition can have any bearing on the final stable dose; a 
more obvious related parameter would be the target INR. Gage et al (2008) 
found that the presence of an active VTE (PE or DVT) increased the warfarin 
dose by 7% (p=0.013) and was significant enough to be included in the final 
algorithm. But the study also included patients with a range of target INRs, 
which could have been responsible for the findings. In the other algorithms, 
clinical details were either not noted (Voora et al, 2005; Zhu et al, 2007) or were 
found not to be significant (Sconce et al, 2005; Wadelius et al, 2009; Zambon et 
al, 2011; IWPC, 2009; Gage et al, 2004). It is worth noting however, that the 
Wadelius and Zambon studies only selected patients with a target INR of 2.5 
and not any other therapeutic ranges. It seems logical to assume, therefore, 
that the target INR, which is determined by the clinical indication for OAT (Table 
1.1) is more likely to have a direct influence on an individual’s warfarin dose 
requirement than the clinical condition, due to the fact that the higher the target
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INR is, the more warfarin would be needed to reach that level of 
anticoagulation.
4.1.4 Coagulation factors and albumin levels (Group 3 patients)
Although some studies have investigated the possible effect of the genotypes of 
the vitamin K dependent coagulation factors II, VII, IX and X (see section 
1.6.1.5), there is no literature on whether the actual plasma levels, i.e. the 
phenotype of these factors, is a possible influencing parameter on the stable 
warfarin dose before OAT induction. Since these factors are affected once 
warfarin therapy has commenced, functional assays of factors II, VII, IX and X 
were performed on a cohort of patients before the initiation of warfarin, to 
assess whether a higher baseline level in any of the four factors could be 
reflected in an eventual higher stable warfarin dose and vice versa. Similarly, as 
approximately 99% of warfarin is albumin bound in vivo (Gage and Lesko, 
2008) and it is only the free drug which is pharmacologically active, samples 
were taken at warfarin initiation for albumin assay, in order to determine 
whether the baseline albumin level had any influence on the stable warfarin 
dose (Table 3.3). This was based on the hypothesis that low albumin levels may 
not be sufficient to bind 99% of the warfarin and therefore more unbound drug 
would be available to affect the coagulation factors, leading to a reduced 
warfarin dose requirement.
Unfortunately the cohort of patients was small (n=20), due partly to the fact that 
many of the patients were new to the clinic and, unlike the construction and 
validation cohorts, did not know the staff. This meant that, despite explaining 
the research project, many felt it would have been a long term commitment and 
therefore refused. Others did not want their DNA analysed, fearing that the data 
would be detrimental to them in the future. In addition, as the patients were not 
known to the clinic staff before attending for their first appointment, many had 
some form of dementia and were not capable of signing the consent form or of 
understanding the information sheet, which had been sent to them several days 
before their clinic visit. The numbers of new patients available for study were 
also significantly reduced due to the fact that all cases of DVT and PE had been 
commenced on warfarin as in-patients, before attending the clinic and, as such, 
the coagulation factor assays could not be performed. Therefore, the remaining
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patients available for study were mainly those diagnosed with AF. However, 
soon after the study began, the Cardiology Department implemented a new 
treatment pathway in which the Cardiology consultants commenced the AF 
patients on three days of warfarin, before referral to the Anticoagulant clinic on 
day 4 for INR monitoring. In all, these problems severely limited the number of 
subjects suitable for this part of the study.
Nevertheless, a small number of subjects (n=20) were assayed for albumin and 
the vitamin K dependent factors, to determine if there was any correlation with 
the eventual stable warfarin dose (Tables 3.14 and 3.15). From the five 
parameters studied, only FIX showed a significant correlation (r= -0.6078 p= 
0.005). Several studies have investigated the possibility of a relationship 
between the coagulation factors and the warfarin dose (Shikata et al, 2004; 
Caldwell et al, 2007; Aquilante et al, 2006), but these have involved sequencing 
SNPs coding for the proteins and it is unclear from the literature what effect any 
of the different alleles have on either their plasma levels (as measured by 
immunological assays) or on their activity (as measured by functional assays). 
Consequently, it is difficult to determine what relationship there may be between 
the various alleles and the warfarin dose. In the papers mentioned above, no 
relationship was shown, however, D’Andrea et al (2008) reported a mutation in 
the factor IX propeptide which caused a selective reduction in its activity during 
warfarin therapy and which occurred in <1.5% of the population studied.
The findings of this study for the factor IX correlation are anomalous. Firstly, the 
correlation is negative, so that a decrease in factor IX activity suggests an 
increase in the warfarin dose. Secondly, as factor IX is part of the intrinsic 
coagulation cascade (see Figure 1.1), it does not affect the prothrombin time 
and therefore the INR. More subjects would need to be studied in order to shed 
more light on this finding.
4.2 The clinical/demographic algorithm
Regression analysis, using the clinical and demographic data from the 
validation cohort (n=47), was performed using the clinical algorithm from this 
study (see section 3.5.1.5), together with three published clinical algorithms 
(Gage et al, 2008, IWPC, 2010 and Zambon et al,2011) and the results are 
shown in Table 4.1.
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Table 4.1 Comparison of the four clinical algorithms using data 
from the validation cohort (n=47)
NB R2 represents the amount of variation in the data which is explained by the 
regression; i.e. R2=0.50 means that 50% of the variation in warfarin dose is 
explained by the algorithm.
This study Gage et al 
(2008)
IWPC
(2010)
Zambon et al 
(2011)
R2 0.188 0.263 0.268 0.203
F ratio 10.413 16.084 16.469 11.138
P 0.002 <0.001 <0.001 0.001
Using the data from the validation cohort (n=47) for each of the algorithms, the 
one produced in this study gave the lowest predictability of the stable warfarin 
dose (R2=0.188). However, there is a wide variation between the results from 
the other three formulae and those stated in their individual papers. Gage et al 
(2008) had a 17% predictability (n=292), IWPC (2010) 26% (n=1009) and 
Zabon et al (2011) 31% (n=97). The overall results appear to confirm the 
difficulty in comparing the inter-algorithm validity due to the different parameters 
included in the formulae and the numbers of subjects in each validation cohort. 
Furthermore, whereas Gage et al (2008) calculated the predictability of the 
clinical algorithm using the whole of their validation cohort data, the Zabon et al 
(2011) cohort was divided into three groups, <3.6mg/day, >3.6<6.4mg/day and 
>6.4mg/day (low, medium and high doses respectively), based on 1.4mg/day 
below or above the standard daily loading dose of 5mg. The predictability for 
each group (16.8%, 56.8% and 9.6% respectively) was used to determine 
whether using the clinical algorithm would have under- or overdosed the 
patients when compared to the standard 5mg daily trial and error approach. 
Similar results were produced by the IWPC (2010) of 24%, 53% and 13% for 
low, medium and high stable doses (<3mg/day, >3<7mg/day and >7mg/day 
respectively. Both studies show that the predictability of their respective clinical
algorithms was highest in the intermediate dose group. In order to do the same, 
the validation cohort for this study was divided into three groups according to 
the interquartile ranges of the stable warfarin dose and the data is shown in 
Table 4.2.
Table 4.2 Predictability of the clinical algorithm in low, medium  
and high warfarin doses in the validation cohort (n=47).
25th quartile = 2.8mg/day
75th quartile = 5.0mg/day
<2.8mg/day
(n=12)
>2.7<5.0mg/day
(n=24)
>5.0mg/day 
(n=11)
R2 0.009 0.077 0.016
F Ratio 0.095 2.075 0.150
P 0.764 0.162 0.708
Although the results show no statistical significance, it is interesting to note that, 
as with Zambon et al (2011) and IWPC (2010), the clinical algorithm has a 
higher predictability in patients who require an intermediate warfarin dose but is 
less effective with the low and high dose groups. This could be explained, at 
least in part, due to the absence in the algorithms of warfarin sensitive or 
resistant SNPs, although a much larger cohort of patients would probably have 
increased the predictability to a level more comparable with the other studies.
4.3 DNA extraction problems
Blood samples were obtained from healthy laboratory staff (Group 1 subjects, 
n=12), for optimisation of the DNA extraction procedure and PCR analysis, in 
order not to use up samples from the warfarin patients. The first extraction 
method, using the QIAamp® DNA mini kit (section 2.6.2.1) produced low yields 
of DNA (mean=9.5 ng/pl, ±SD 1.71), which failed to show any allelic 
discrimination with a common SNP assay. Various modifications to the
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methodology were performed, including the precipitation of any haem 
contamination, but the DNA yields and PCR results did not improve. The results 
were unexplainable, even though the extraction method provided by the 
QIAamp® kit was followed implicitly.
Because a large amount of the healthy control samples had been used, a small 
number of group 1 samples (n=4) were selected for the Whatman® extraction 
method (Table 3.5). These produced a much higher DNA yield (mean=21.3 
ng/pl, ±SD 7.33) and all but one showed clear allelic discrimination (Figure 3.3); 
the negative result for sample 1 may have been due to a pipetting error. This 
method was then used for the DNA extraction on all the warfarin patient 
samples (groups 2 and 3 subjects). The final Whatman ® extraction procedure 
proved to be the cheapest and quickest method for isolating a substantial yield 
of DNA from the FTA® Elute cards.
4.4 Pharmacogenetic data; a comparison of the frequencies with the other 
published algorithm studies
The SNPs which have been shown beyond doubt to cause a significant 
reduction of the stable warfarin dose (Gage, 2006) are VKORC1 and CYP2C9 
(see sections 1.6.1.1-1.6.1.3). In addition, Caldwell et al, (2008) discovered that 
the CYP4F2 SNPs have the effect of increasing the warfarin requirement. The 
majority of these studies have simply investigated the relationship between the 
warfarin dose and the presence of the polymorphisms, but a few have used the 
data in order to design algorithms which, together with clinical and demographic 
data, have been able to improve the predictability of warfarin dosing beyond 
that of simple clinical algorithms (Gage et al, 2004; Sconce et al, 2005; Voora et 
al, 2005; Zhu et al, 2007; Gage et al, 2008; IWPC, 2009; Wadelius et al, 2009; 
Zambon et al, 2011). Although there have been more published algorithms, 
these ones were chosen for comparison with the formula produced in this study 
(section 3.6.2) as the ethnicity of the subjects in the data used had no effect on 
the final outcome.
4.4.1 Comparison of the VKORC1 and CYP2C9 SNP frequencies from this 
study with the chosen algorithms. The frequencies of the VKORC1 and 
CYP2C9 SNPs from this study and some of the chosen algorithm papers are 
shown in Table 4.3.
90
Table 4.3 Comparison of the SNP frequencies for VKORC1 and CYP2C9 with those 
from six published algorithm studies.
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The frequencies of some SNPs are not shown; Gage et al (2008) did not state 
the frequency of either gene, Gage et al (2004) and Voora et al (2005) did not 
analyse the VKORC1 gene and Gage et al (2004) and Zhu et al (2007) did not 
subdivide the frequencies of the individual CYP2C9 SNP combinations. Those 
studies which did state the individual SNP frequencies compare favourably to 
those from this study. With the exception of Zhu et al (2007), who only used a 
small cohort of patients (n=65), all the algorithms showed that the heterozygous 
GA allele for VKORC1 was more prevalent than either of the homozygous 
alleles GG and AA.
For the CYP2C9 alleles, all the studies demonstrated a decrease in the 
frequency from the wild type (*1/*1) through to the rare *3/*3 SNP, except Voora 
et al (2005) with a study consisting of 48 subjects.
4.4.2 Comparison of the CYP4F2 SNP frequencies from this study with the 
chosen algorithms
Since its discovery by Caldwell et al (2008), several studies have recently been 
published which have examined the effect of the CYP4F2 SNPs on warfarin 
dosing (Carlquist et al, 2010; Pautas et al, 2010; Wells et al, 2010; Kringen et 
al, 2011; Zambon et al, 2011). The frequencies of the three alleles (CC-wild 
type, CT and TT) from these papers and from this study are compared in Table 
4.4. All the studies, with the exception of Carlquist et al (2010), were conducted 
on Caucasian subjects and a comparison of the frequencies shows a distinct 
similarity for each allele, with CC having the highest occurrence and TT the 
lowest.
In summary, the frequencies for both the wild type and the variant alleles of 
VKORC1, CYP2C9 and CYP4F2 from this study are of comparable levels to 
those found in the chosen published algorithms.
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Table 4.4 Comparison of the SNP frequencies for CYP4F2 with those from
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4.5 The pharmacogenetic algorithm
The chosen published pharmacogenetic algorithms and the one constructed in 
this study were used to calculate a predicted warfarin dose, using the relevant 
data from the validation patient cohort (n=47). Regression analysis was then 
performed on the resultant doses for each algorithm in order to compare the 
predicted and actual warfarin doses and the data is shown in Table 4.5.
Each individual paper containing the chosen algorithms states a different 
predictability with their own patient cohort than was found with the validation 
cohort from this study. However, the data shown in Table 4.5 compares all the 
algorithms with the same data set; all formulae show a high level of significance 
(p<0.001) with varying degrees of predictability (R2 0.309-0.553). The algorithm 
from this study produced the highest R2 value (0.553), indicating that 55.3% of 
the warfarin dose variability can be explained by using this formula. This 
suggests that, by including as many clinical, demographic and genetic 
parameters as can be shown to have a significant influence on the warfarin 
dose, the efficacy of the algorithm can be improved.
4.6 Limitations of the study
As with many projects of this type, increasing the number of participants would 
have been expected to consolidate the outcomes reported here. Despite the 
fact that the pharmacogenetic algorithm from this study showed the highest 
warfarin dose predictability among all the chosen algorithms, there still remains 
approximately 45% of the dose variability which is unaccounted for. By 
increasing the number of patients in both the construction and validation 
cohorts, more examples of the long term drugs which interact with warfarin (i.e. 
simvastatin, omeprazole and aspirin) may have shown a significant correlation.
An increase in both cohorts may also have led to an improvement in the 
predictability of the clinical algorithm, which would be more useful to the 
majority of district general hospitals, as these usually do not have the capability 
for PCR SNP analysis. Furthermore, a much larger number of group 3 pre­
warfarin patients would be necessary to definitively prove whether or not the 
baseline levels of the vitamin K dependent clotting factors and albumin were an
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Table 4.5 Regression analysis comparison of the chosen pharmacogenetic algorithms 
with the one from this study using the validation cohort data (n=47)
Zambon et 
al (2011)
COCOm-o
COLOCO
<0.001
Wadelius et 
al (2009)
COCO■"sTd
CDCMocm
oodV
IWPC
(2009)
LOCMLOd
49.676
oodV
Gage et al 
(2008)
CDoCOd
20.095
oodV
Zhu et al 
(2007)
00oLOo
46.367
oodV
Voora et al 
(2005)
CO00COd
27.928
oodV
Sconce et al 
(2005)
toT—LOd
47.699
oodV
Gage et al 
(2004)
CO00COd
27.928
oooV
This study
COLOLOd
55.627
oodV
CMO'
F ratio
Q.
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Influence on the eventual stable warfarin dose, thereby improving both 
algorithms. This would also have helped to determine if the correlation between 
the warfarin dose and the factor IX levels was an anomaly or a true relationship.
Only Caucasian subjects were chosen for this study as previously stated 
(section 2.2). A larger study, which included a statistically significant number of 
ethnic groups, would have been preferable. However, in order to include other 
races and therefore a wider genetic variation, it would have been necessary to 
include many more SNPs in the study.
This study did not include any measurement of either alcohol or vitamin K 
intake. Trying to evaluate these parameters by patient self-assessment is 
unreliable, subjective and has been shown to have no significant correlation 
with the stable warfarin dose (Aquilante et al, 2006). However, Kamali et al 
(2000b) assayed plasma vitamin K levels and did find a significant relationship; 
however, the cost of establishing a vitamin K assay in most hospitals would be 
prohibitive.
4.7 The future of warfarin
Since this study was started, two new anticoagulant drugs have become 
available which have the potential to replace warfarin for a large number of 
patients. Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim) is an oral anti­
thrombin drug and has been approved for the prevention of stroke in non- 
valvular AF patients (National Institute for Clinical Excellence Guidelines, March 
2012), with a dose of 110mg or 150mg twice daily. The second drug, 
Rivaroxaban (Xarelto®, Bayer) is an anti-Xa drug which is administered orally 
once daily and has been approved for the treatment and prevention of DVT and 
PE in patients requiring anticoagulation for less than twelve months (National 
Institute for Clinical Excellence Guidelines, July 2012).
Both drugs have several advantages and disadvantages when compared to 
warfarin. Firstly, neither Dabigatran nor Rivaroxaban require any laboratory 
monitoring, as there is no definitive assay at the present time which correlates 
with the dose in a similar way to the INR and warfarin therapy. This has 
significant advantages for the patients, who do not have to arrange their 
working or social lives around frequent blood tests. However, this also means
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that any severe suppression of the coagulation mechanism cannot be detected 
until the patient presents with some evidence of haemorrhage. Secondly, non- 
compliance is not uncommon among warfarin patients, especially in the elderly 
with memory problems, which is only required to be taken once daily; in the 
case of Dabigatran, which is administered twice daily, there may be an increase 
in non-compliant events.
At the present time, Dabigatran and Rivaroxaban are much more expensive, at 
approximately £2.52 per day (National Institute for Clinical Excellence 
Guidelines, March 2012), when compared to a 5mg/day warfarin dose which 
costs £0.03 (British National Formulary. December 2011). The cost differential 
should decrease in time with an increase in use of the new anticoagulants but, 
in the present economic climate, clinicians may be reticent to prescribe them in 
order to prevent a sharp increase in their drug budget spending.
Despite the pros and cons, Dabigatran and Rivaroxaban are the closest that the 
pharmaceutical industry has come to replacing warfarin in over fifty years and 
they offer a real alternative which may irrevocably alter the way patients are 
anticoagulated in the future.
4.8 Future study
Despite the advent of the new anticoagulant drugs, warfarin will most likely be 
the drug of choice for many clinicians for the foreseeable future. In this case, 
any protocol which has the potential to minimise the occurrence of adverse 
events and maximise the time in the therapeutic range for warfarin patients has 
to be beneficial for their safety and wellbeing. Therefore, the next step from this 
study should be an attempt to increase the predictability of both the clinical and 
pharmacogenetic algorithms, using a much larger cohort of subjects; this would 
also help in determining whether the baseline coagulation factors and albumin 
have any significant effect on the stable warfarin dose. Once the algorithms 
have been constructed, they should both be used in a randomised clinical trial, 
together with the present trial-and-error dosing approach, to determine which 
method produces the least number of adverse events as well as increasing the 
time spent in the therapeutic range and decreasing the time taken to reach it. 
Such a study would need to include as many representatives of ethnic groups 
as well as SNP variations as possible, especially the newly reported VKOR
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3730G>A SNP, which has been associated with an increase in the warfarin 
dose requirement (Carlquist et al, 2010; Cini et al, 2012).
4.9 Summary
For almost sixty years, warfarin has been the principle drug of choice for the 
long term prevention and treatment of VTE and it has been estimated that 
approximately 500,000 people are taking oral anticoagulant therapy in the UK 
alone (Baglin et al, 2006). Although many of the demographic and clinical 
factors which affect the pharmacological actions of warfarin have been known 
for many years, it is only recently that the area of pharmacogenetics has 
opened up a whole new field of anticoagulant study. As a consequence, our 
understanding of the mechanisms of warfarin action has improved and the 
subsequent development of pharmacogenetic algorithms has, for the first time, 
provided clinicians and scientists with a tool for increasing the safety of warfarin 
dosing. However, there is still an on-going debate as to the value of such 
algorithms, not only due to the emergence of new therapies which do not 
require laboratory monitoring or dose titration, but also because of the expense 
of PCR analysis and the time taken to obtain a result.
Nevertheless, these algorithms do provide a clearer guideline as to the stable 
warfarin dose for an individual patient than either the trial and error approach or 
the protocols devised by studies such as Fennerty et al (1984) and Tate and 
Sefcick (1997). With advances in technology, it is possible that the time taken to 
perform the SNP assays may be reduced to hours instead of days in the near 
future, but this idea must be tempered with the fact that the new oral 
anticoagulant therapies would completely negate the need for algorithms 
altogether if and when they become the drugs of choice. In the meantime, the 
number of people worldwide who are taking warfarin remains very large and 
any system which can be proven to increase the effectiveness and safety of its 
use can only be beneficial to those patients.
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Appendix I Ethical approval
Leeds (Central) Research Ethics Committee
Room 23 
Floor CD
Block 40 King Edward Home 
Leeds General Infirmary 
LS1 3 EX
Telephone: 0113 3923772 
Facsimile: 0113 3922863
17 September 2009
Mr John Barraclough
Specialist Biomedical Scientist
Calderdale & Huddersfield NHS Foundation Trust
Dept, of Haematology,
The Royal Infirmary, Acre St.,
Lindley, Huddersfield.
HD33EA
Dear Mr Barraclough
Study Title: Pharmacogenetic, clinical and demographic factors in
the management of warfarin therapy.
REC reference number: 09/H1313/54
Protocol number: 1.0
Thank you for your letter of 11 September 2009, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation.
The further information has been considered on behalf of the Committee by the Vice- 
Chair.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below.
Ethical review of research sites
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below).
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start 
of the study.
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned.
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For NHS research sites only, management permission for research (“R&D approval”) should be 
obtained from the relevant care organisation(s) in accordance with NHS research governance 
arrangements. Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System or at http://www.rdforum.nhs.uk. Where the only 
involvement o f the NHS organisation is as a Participant Identification Centre, management 
permission fo r research is not required but the R&D office should be notified o f the study. 
Guidance should be sought from the R&D office where necessary.
Sponsors are not required to notify the Committee o f approvals from host organisations.
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable).
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Version Date
Evidence of insurance or indemnity 01 August 2009
Approval letter from University 09 July 2009
Supervisor CV
Statistician Comments 27 April 2009
Peer Review 12 February 2009
Letter from Sponsor 17 August 2009
Protocol 1.0 22 July 2009
Investigator CV
REC application 17 July 2009
Participant Information Sheet: Staff 1.2 31 July 2009
Participant Information Sheet: Patient 1.2 05 September 2009
Participant Information Sheet: Patient 2.2 05 September 2009
Participant Consent Form: Staff 1.2 05 September 2009
Participant Consent Form: Patient 1.2 05 September 2009
Response to Request for Further Information 11 September 2009
Participant Consent Form: Patient 2.2 05 September 2009
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website.
The attached document “After ethical review -  guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:
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• Notifying substantial amendments
• Adding new sites and investigators
• Progress and safety reports
• Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve 
our service. If you would like to join our Reference Group please email 
referenceqroup@nres.npsa.nhs.uk.
09/H1313/54_________________ Please quote this number on all correspondence
Yours sincerely
Dr Margaret L Faull 
Chair
Email: rachelt.bell@leedsth.nhs.uk
Enclosures: “After ethical review -  guidance for researchers”
Copy to: Mr Brian Littlejohn
R&D office for Calderdale and Huddersfield NHS Foundation Trust
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3rd floor, Learning Centre 
Huddersfield Royal Infirmary 
Llndley 
Huddersfield 
West Yorkshire 
HD33EA
Telephone: 01484 347007
Fax: 01484 347215
Email: r&d@cht.nhs.uk
Mr John Barraclough
Specialist Biomedical Scientist
Dept Haematology
Huddersfield Royal Infirmary
Llndley
Huddersfield
HD33EA
17th September 2009
Dear Mr Barraclough
ID: 775 Pharmacogenetlc, clinical and demographic factors In the management of
warfarin therapy.
The Research and Development department has considered the following documents in support of 
your application for approval to undertake the study on the premises of Calderdale and 
Huddersfield NHS Foundation Trust:
D o c u m e n t , V e rs io n -  f d a te d
Proposal Document 15033443 14/05/2008
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PIS -  staff 1.1 22 /07/09
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Consent form-staff 1.1 22/07/2009
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Your study now has R&D approval on the understanding and provision that you will adhere to the 
following conditions:
That the research should:
• Comply with the requirements of The Research Governance Framework for Health and Social Care (2nd DH 
2005);
• Comply with regulatory requirements and legislation relating to: Clinical Trials, Data Protection, Health 
• and Safety, Trust Caldicott Guidelines, and the use of Human Tissue for research purposes;
• Be conducted in accordance with: ICH Good Clinical Practice and/or the MRC guidelines for good clinical 
practice (as appropriate);
• Not commence until it has received written approval from a UKECA recognised Research Ethics 
Committee (REC) and that any REC imposed conditions of that approval are implemented;
You must also:
• Request written approval for any change to the approved protocol/study documents that you or the 
Chief Investigator wish to implement;
• Ensure that all study personnel, not employed by Calderdale and Huddersfield NHS Foundation Trust, hold 
either an honorary contract with the Trust or a letter of access issued by the Trust, before they have 
access to any facilities, patients, staff, their data, tissue or organs;
• Complete the Research Governance interim and final reports as requested;
• Submit monthly recruitment and screening data to R&D (if applicable).
• Comply with our audit and monitoring procedures as required.
This approval letter constitutes a favourable Site Specific Assessment (SSA) for this site.
Please be aware that the R&D department has a database containing study related information, and personal 
information about individual investigators e.g. name address, contact details etc. This information will be 
managed according to the principles established in The Data Protection Act
yours sincerely
Dr David Birkenhead
Director of Research and Development
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Appendix III Group 1 subject information sheet
Calderdale and Huddersfield
NHS Foundation TrustAnticoagulant Dept 
Huddersfield Royal Infirmary 
Lindley,
Huddersfield HD3 3EA 
Tel 01484 347258 
Fax 01484 342843
Staff Volunteer Information Sheet Version Staff 1.2
Pharmacogenetie, clinical and demographic factors in the 
management of warfarin therapy
You are being invited to take part in a research study as part o f  a 
Professional Doctorate degree. Before you decide, it is important fo r  you to 
understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with 
your colleagues i f  you wish. Please ask i f  there is anything that is not clear 
or i f  you would like more information.
What is the purpose of the study?
As you may be aware, finding the optimum dose of warfarin for a given 
patient, in order to maintain the INR in the therapeutic range, is not 
straightforward; there are many variables which influence oral 
anticoagulant dosing, including age, body size, gender etc. In recent years, 
three single nucleotide polymorphisms (SNPs) have been identified in two 
genes that are involved in the action and metabolism of warfarin. These 
SNPs, if present, significantly increase the response to warfarin and so 
these patients require a lower dose than the majority of the population in 
order to reach a therapeutic level. As a consequence several researchers 
have developed mathematical formulae, or algorithms, which take into 
account many of the variables associated with warfarin dosing, including 
these SNPs, thereby allowing clinicians to predict an individual’s optimum 
dose before commencing treatment.
05/09/09 version Staff 1.2
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The aim of this study is to collect data on many of the known variables 
from existing, warfarin patients and to develop a new algorithm, which will 
give a higher prediction rate than the existing ones. Part of the research will 
be to test patients for the three SNPs using polymerase chain reaction 
(PCR).
However, in order to ensure that the PCR technique works correctly, I 
would like to perform a pilot study using a small number of staff before 
collecting samples on patients.
What will it involve if I agree?
I f  you agree to take part you will be asked to sign a consent form and one 
or two drops of blood will be taken from a fingerprick for PCR analysis.
What will happen to the blood sample?
The fingerprick sample will be spotted onto a card, which w ill release the 
DNA from the leucocytes and maintain it in a stable condition prior to 
analysis. Once the PCR technique has been verified, all remaining samples 
w ill be destroyed according to normal laboratory procedures. Your blood 
w ill not be tested for any other genes, such as those associated with other 
diseases.
When will the pilot study take place?
It is hoped that sample collection will begin early in 2010.
Will my results be kept confidential?
Yes. A ll samples and the information obtained from them w ill be identified 
by a random number only and will not be traceable back to the participant.
What will happen to the results of the pilot study?
As stated above, your individual results w ill not be passed directly on to 
you or anyone else. The collective results w ill only be used to verify the 
PCR technique. These data will be included in the final thesis and any 
scientific publications that arise from it. No names will be used and it will 
not be possible to identify you from any publication of the results.
Thank you for your time
John Barraclough MPhil. CSci. FIBMS Tel ext.7258
05/09/09 version Staff 1.2
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Appendix IV Group 2 subject information sheet
Calderdale and Huddersfield
NHS Foundation Trust
Anticoagulant Dept 
Dept, of Haematology,
Huddersfield Royal Infirmary,
Lindley, Huddersfield, HD3 3EA.
Tel 01484 347258 
Fax 01484 342843
Patient Information Sheet Version Patient 1.2 
Pharmacogenetic, clinical and demographic factors in the management 
of warfarin therapy
You are being invited to take part in a study, which is part o f  a 
Professional Doctorate degree. Before you decide it is important fo r  you to 
understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with 
friends, relatives and your GP i f  you wish. Ask us i f  there is anything that is 
not clear or i f  you would like more information. Take time to decide 
whether or not you wish to take part.
What is the purpose of the study?
As you may be aware, finding the correct dose of warfarin for a patient is 
not straightforward. There are many factors which influence this, including 
age, body size, gender and genetics etc.
The aim of this study will be to collect data from existing warfarin patients 
in order to develop a better way of finding out the correct warfarin dose in 
new patients much more quickly than at present.
Why have I been chosen?
You have been chosen because you have been taking warfarin long enough 
for your dose to be relatively stable.
What will it involve if  I agree to take part in the study?
If you agree to take part you will be asked to donate an extra drop or two of 
blood from the fingerprick site, after enough has been taken for your 
routine test. You will not have to attend a separate appointment to donate 
this blood and you will not have to have more than the usual single 
fingerprick. If you do agree to take part, this blood sample will be taken the 
next time you are seen in clinic.
05/09/09 version Patient 1.2
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In addition, we will ask one of the nurses to measure your height and 
weight, while you are waiting for your usual blood result. We will also ask 
you to bring an up-to-date list of all your other medications, as these may 
have an effect on your warfarin treatment.
Do I have to take part?
It is up to you to decide whether or not to take part. I f  you decide to take 
part, you w ill be given this information sheet to keep and be asked to sign a 
consent form. By signing the consent form you are saying that you are 
happy to take part in the study and that you understand what has been 
explained to you.
What will happen to my blood?
Your blood will be processed in the laboratory at a later date. Your genetic 
material, or DNA, will be analysed to see if  you possess one of the genes 
responsible for making people more sensitive to warfarin than others. Your 
blood will not be tested for any other genes, such as those associated with 
other diseases. Once the test has been done, any sample left over will be 
destroyed using normal laboratory procedures.
What are the possible disadvantages and risks of taking part?
There will be no risks or disadvantages. Apart from measuring your weight 
and height and taking a drop or two more of blood from the fingerprick, the 
clinic visit w ill be exactly the same as usual.
What are the possible benefits of taking part?
There are no direct benefits to you from taking part in this study at this 
stage. However, it is hoped that, once the study has been completed, we 
will be able to dose patients who are starting warfarin therapy much more 
accurately.
When will the study be completed?
The study should be completed late in 2010.
Will my taking part in this study be kept confidential?
Yes. A ll information we obtain from you w ill be kept on a computer 
database, using only your hospital number as identification. No names, 
addresses or dates of birth will be used. When the study has been 
completed, the database will be destroyed.
What will happen to the results of this study?
Your individual results will not be directly passed on to you. The 
collective results from all the patients who are included in the study may be 
presented in a scientific publication to aid other doctors and scientists
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managing patients on warfarin. No patient names w ill be used and it will 
not be possible to identify you from any publication of the results of the 
study.
Will I be paid for taking part?
We regret you w ill not be paid for taking part.
Who has reviewed this study?
This study has been reviewed and approved by the Leeds Central Research 
Ethics Committee and the Sheffield Hallam University Ethics Committee.
What if something goes wrong?
I f  you are harmed by taking part in this research project, there are no 
special compensation arrangements. I f  you are harmed due to someone’s 
negligence, then you may have grounds for legal action but you may have 
to pay for it. Regardless of this, if  you wish to complain about any aspect of 
the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanism may be 
available to you.
Contact for further information
Further information about this study can be obtained by contacting Mr. 
John Barraclough, Anticoagulation Department, Huddersfield Royal 
Infirmary, Acre, St., Lindley, Huddersfield, HD3 3EA, telephone number 
01484 347258.
What if I wish to complain about the way in which the study has been 
conducted?
I f  you have any cause to complain about any aspect of the way in which 
you have been approached or treated during the course of the study, the 
normal National Health Service complaints mechanisms are available to 
you and are not compromised in any way because you have taken part in a 
research study.
I f  you have any complaints or concerns please contact the project co­
ordinator: Mr. John Barraclough, telephone number 01484 347258.
Thank you very much for reading through this information sheet and please 
remember to bring an up-to-date list of all your current medications.
John Barraclough MPhil. CSci. FIBMS
05/09/09 version Patient 1.2
118
Appendix V Group 3 subject information sheet
Calderdale and Huddersfield
NHS Foundation Trust
Anticoagulant Dept 
Dept, of Haematology,
Huddersfield Royal Infirmary,
Lindley,
Huddersfield, HD3 3EA.
Tel 01484 347258 
Fax 01484 342843
Patient Information Sheet Version Patient 2.2 
Pharmacogenetic, clinical and demographic factors in the 
management of warfarin therapy
You are being invited to take part in a study, which is part o f  a 
Professional Doctorate degree. Before you decide it is important fo r you to 
understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with 
friends, relatives and your GP i f  you wish. Ask us i f  there is anything that is 
not clear or i f  you would like more information. Take time to decide 
whether or not you wish to take part.
What is the purpose of the study?
As you may be aware, finding the correct dose of warfarin for a patient is 
not straightforward. There are many factors which influence this, including 
age, body size, gender and genetics etc.
The aim of this study will be to collect data from new patients in order to 
develop a better way of finding out the correct warfarin dose in new 
patients much more quickly than at present.
Why have I been chosen?
You have been chosen because you are about to start warfarin treatment 
and therefore your clotting mechanism has not yet been affected.
What will it involve if  I agree to take part in the study?
If you agree to take part you will be asked to donate an extra drop or two of 
blood from the fingerprick site, after enough has been taken for your 
routine test. You will not have to attend a separate appointment to donate 
this blood and you will not have to have more than the usual single 
fingerprick. If you do agree to take part, this blood sample will be taken the 
first time you are seen in clinic.
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Patients new to warfarin are normally asked to have a blood sample taken 
from their arm, in order to check their general health. We need to ask your 
permission to use some of the blood left over for this research project. You 
will not be asked to have any more blood tests than is usual. In addition, we 
will ask one of the nurses to measure your height and weight, while you are 
waiting for your usual blood result. We will also ask you to bring an up-to- 
date list of all your other medications, as these may have an effect on your 
warfarin treatment.
Do I have to take part?
It is up to you to decide whether or not to take part. I f  you decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. By signing the consent form you are saying that you are 
happy to take part in the study and that you understand what has been 
explained to you.
What will happen to my blood?
Your blood w ill be processed in the laboratory at a later date. Your genetic 
material, or DNA, will be analysed to see if  you possess one of the genes 
responsible for making people more sensitive to warfarin than others. Your 
blood will not be tested for any other genes, such as those associated with 
other diseases. Once the test has been done, any sample left over w ill be 
destroyed using normal laboratory procedures.
What are the possible disadvantages and risks of taking part?
There w ill be no risks or disadvantages. Apart from measuring your weight 
and height and taking a drop or two more of blood from the fingerprick, the 
clinic visit w ill be exactly the same as for all patients.
What are the possible benefits of taking part?
There are no direct benefits to you from taking part in this study at this 
stage. However, it is hoped that, once the study has been completed, we 
will be able to dose patients who are starting warfarin therapy much more 
accurately.
When will the study be completed?
The study should be completed early in 2011.
Will my taking part in this study be kept confidential?
Yes. A ll information we obtain from you will be kept on a computer 
database, using only your hospital number as identification. No names, 
addresses or dates of birth will be used. When the study has been 
completed, the database will be destroyed.
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What will happen to the results of this study?
Your individual results will not be directly passed on to you. The 
collective results from all the patients who are included in the study may be 
presented in a scientific publication to aid other doctors and scientists 
managing patients on warfarin. No patient names will be used and it will 
not be possible to identify you from any publication of the results of the 
study.
Will I be paid for taking part?
We regret you will not be paid for taking part.
Who has reviewed this study?
This study has been reviewed and approved by the Leeds Central Research 
Ethics Committee and Sheffield Hallam University Ethics Committee.
What if something goes wrong?
I f  you are harmed by taking part in this research project, there are no 
special compensation arrangements. I f  you are harmed due to someone’s 
negligence, then you may have grounds for legal action but you may have 
to pay for it. Regardless of this, if  you wish to complain about any aspect of 
the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanism may be 
available to you.
Contact for further information
Further information about this study can be obtained by contacting Mr. 
John Barraclough, Anticoagulation Department, Huddersfield Royal 
Infirmary, Acre, St., Lindley, Huddersfield, HD3 3EA, telephone number 
01484 347258.
What if I wish to complain about the way in which the study has been 
conducted?
I f  you have any cause to complain about any aspect of the way in which 
you have been approached or treated during the course of the study, the 
normal National Health Service complaints mechanisms are available to 
you and are not compromised in any way because you have taken part in a 
research study.
I f  you have any complaints or concerns please contact the project co­
ordinator: Mr. John Barraclough, telephone number 01484 347258.
Thank you very much for reading through this information sheet.
Thank you for your time
John Barraclough MPhil. CSci. FIBMS Tel Hudds. 347258
05/09/09 version Patient 2.2
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Appendix VI Group 1 subject consent form
Calderdale and Huddersfield
NHS Foundation Trust
Anticoagulant Dept.,
Dept, of Haematology,
Huddersfield Royal Infirmary,
Lindley, Huddersfield,
HD3 3EA.
Tel 01484 347258 
Fax 01484 342843
Study Number: 09/H1313/54
Staff Identification Number for this project:
CONSENT FORM
Title of Project: Pharmacogenetic, clinical and demographic factors in the management of warfarin
therapy.
Name of Researcher: Mr. John Barraclough
1. I confirm that I have read and understand the information sheet dated 
22/07/09 (version Staff. 1.2) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
Calderdale & Huddersfield NHS Foundation Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 
have access to my records.
4. I agree to take part in the above study.
Name of Staff Member Date Signature
Name of Person Date Signature
Taking consent
Copies: 1 for staff member, 1 for researcher site file.
05/09/09 version Staff 1.2
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Appendix VII Group 2 subject consent form
Calderdale and Huddersfield
NHS Foundation Trust
Anticoagulant Dept.,
Dept, of Haematology 
Huddersfield Royal Infirmary,
Lindley, Huddersfield, HD3 3EA.
Tel 01484 347258 
Fax 01484 342843
Study Number: 09/H1313/54
Patient Identification Number for this project:
CONSENT FORM
Title of Project: Pharmacogenetic, clinical and demographic factors in the management of warfarin
therapy.
Name of Researcher: Mr. John Barraclough
1. I confirm that I have read and understand the information sheet dated —
05/09/09 (version Patient 1.2) for the above study. I have had the opportunity
to consider the information, ask questions and have had these answered 
satisfactorily.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
Calderdale & Huddersfield NHS Foundation Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 
have access to my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person Date Signature
Taking consent
Copies: 1 for patient, 1 for researcher site file, 1 (original) to be kept in medical notes
05/09/09 version Patient 1.2
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Appendix VIII Group 3 subject consent form
Calderdale and Huddersfield
NHS Foundation Trust
Anticoagulant Dept.,
Dept, of Haematology,
Huddersfield Royal Infirmary,
Lindley, Huddersfield,
HD3 3EA.
Tel 01484 347258 
Fax 01484
342843
Study Number: 09/H1313/54
Patient Identification Number for this project:
CONSENT FORM
Title of Project: Pharmacogenetic, clinical and demographic factors in the management of warfarin
therapy.
Name of Researcher: Mr. John Barraclough
1. I confirm that I have read and understand the information sheet dated --------------
05/09/09 (version Patient 2.2) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
Calderdale & Huddersfield NHS Foundation Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 
have access to my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person 
Taking consent
Date Signature
Copies: 1 for patient, 1 for researcher site file, 1 (original) to be kept in medical notes
05/09/09 version Patient 2.2
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Appendix IX Fennerty et al (1984) dosing schedule
Day
1
2 (16hrs post 1st dose)
3 (16hrs post 2 nd dose)
4 (16hrs post 3rd dose)
INR
<1.4 
< 1.8 
« 1.8 
> 1.8 
r <2.0 
2.0-2.1
2 .2- 2.3
2.4-2.5
2.6-2.7 
/  2 .8-2.9
3.0-3.1
3.2-3.3
3.4
3.5
3.6-4.0 
 ^ >4.0
r  < 1.4
1.4
1.5
1 .6 - 1.7 
1.8 
1.9
2 .0-2.1 
< 2 .2-2.3
2.4-2.6
2.7-3.0
3.1-3.5 
3.6-4.0
4.1-4.5 
V>4.5
Warfarin 
Dose (mg)
10.0
10.0
1.0
0.5
10.0
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0 
0.5 
Nil
Predicted dose 
> 8.0 
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
Miss 1 day then 2mg 
Miss 2 days then 1mg
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Appendix X Tait and Sefcick (1997) dosing schedule 
Dav 5 INR Dose for davs 5-8 Dav 8 INR Dose from dav 8
<1.7 5mg
<1.7 
1.8-2.4 
2.5-3.0 
>3.0
6mg
5mg
4mg
3ma for 4 days
<1.7 5mg
1.8-2.4 4mg
1.8-2.2 4mg 2.5-3.0 3.5mg
3.1-3.5 3mg for 4 days
>3.5 2.5ma for 4 days
<1.7 4mg
1.8-2.4 3.5mg
2.3-2.7 3mg 2.5-3.0 3mg
3.1-3.5 2.5mg for 4 days
>3.5 2mq for 4 davs
<1.7 3mg
1.8-2.4 2.5mg
2.8-3.2 2mg 2.5-3.0 2mg
3.1-3.5 1.5mg for 4 days
>3.5 1ma for 4 days
<1.7 2mg
1.8-2.4 1.5mg
3.3-3.7 1mg 2.5-3.0 1mg
3.1-3.5 0.5mg for 4 days
>3.5 omit for 4 davs
<2.0 1.5mg for 4 days
>3.7 Omg 2.0-2.9 1mg for 4 days
3.0-3.5 0.5mg for 4 days
All patients with a baseline INR .4 were given 5mg/day for 4 days
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Appendix XI Chosen published algorithms 
Zambon etal, 2011:
Dose (mg/week) = [7.39764 - (0.02734 x age) + (1.06287 x BSA)
- (1.04468 XVKORC1 AG) - (2.12117 x VKORC1 AA)
- (0.78983 x CYP2C9*1/*2) - (1.17138 x CYP2C9*1/*3)
- (1.81292 x CYP2C9*2/*2 or *2/*3 or *3/*3)
- (0.46723 x CYP4F2 CT) - (0.71528 x CYP4F2 CC)]2
where: age (in years) and BSA (in m2)
Gage etal, 2004:
Dose (mg/day) = exp[0.385 - (0.0083 x age) + (0.498 x BSA)
- (0.208 x CYP2C9*2) - (0.350 x CYP2C9*3)
- (0.341 x amiodarone) + (0.378 x target INR)
- (0.126 x simvastatin) - (0.113 x race)
- (0.075 x female)]
where: exp = exponential function
age (in years) and BSA (in m2)
CYP2C9 = 0 (absent), 1 (heterozygous) or 2 (homozygous) 
amiodarone/simvastatin = 1 (present) or 0 (absent) 
race = 1 (Caucasian) or 2 (other) 
female = 1, male = 0
Gage etal, 2008:
Dose (mg/day) = exp[0.9751- (0.3238 x VKORC1 AA) + (0.4317 x BSA)
- (0.4008 x CYP2C9*3) - (0.00745 x age)
- (0.2066 x CYP2C9*2) + (0.2029 x target INR)
- (0.2538 x amiodarone) + (0.0922 x smokes)
- (0.0901 x Afro American) + (0.0664 x DVT/PE)]
where: exp = exponential function
age (in years) and BSA (in m2)
Afro American = 1 other = 0
amiodarone = 1 (present) or 0 (absent)
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smokes = 1 for a smoker or 0 for a non-smoker 
DVT/PE = 1 (if initial diagnosis was DVT or PE), others = 0
IWPC, 2009:
Dose (mg/week) = [5.6044 - (0.2614 x age) + (0.0087 x height)
+ (0.0128 x weight) - (0.8677 x VKORC1 GA)
- (1.6974 x VKORC1 AA) - (0.5211 x CYP2C9*1/*2)
- (0.9357 x CYP2C9*1*3) - (1.0616 x CYP2C9*2*2)
- (1.9206 x CYP2C9*2*3) - (2.3312 x CYP2C9*3*3)
- (0.1092 x Asian) - (0.2760x Black) - (0.1032 x mixed race)
+ (1.1816 x CYP enzyme inducer drugs)
- (0.5503 x amiodarone)]2
where: age (in decades), weight (in kilos) and height (in centimetres)
Asian, Black or mixed race = 1, others = 0
CYP enzyme inducers = phenytoin, carbamazepine or rifampicin
amiodarone = 1 (present) or 0 (absent)
Sconce etal, 2005:
VDose (mg/day) = [0.628 - (0.0135 x age) - (0.240 x CYP2C9*2)
- (0.370xCYP2C9*3) - (0.241 x VKORC1)
+ (0.0162 x Height)]
where: age (in years)
CYP2C9 *2 and *3 = 0, 1 or 2 for the number of alleles present 
VKORC1 = 1 (for GG), 2 (for GA) and 3 (for AA)
Height = centimetres
Voora etal, 2005:
Dose (mg/week) = exp [0.385 - (0.0083 x age) + (0.498 x BSA)
- (0.208 x CYP2C9*2) - (0.350 x CYP2C9*3)
- (0.341x amiodarone) + (0.378 x target INR)
- (0.125 x statin) - (0.0113 x race) - (0.075 x female)]
where: exp = exponential function
age (in years) and BSA (in m2)
CYP2C9 *2 and *3 = 0, 1 or 2 for the number of alleles present
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amiodarone/simvastatin/fluvastatin = 1 (present) or 0 (absent) 
race = 1 (Caucasian) or 0 (other) 
female = 1, male = 0
Wadelius etal, 2009:
Dose (mg/week) = [9.46832 - (0.90112 x VKORC1 GA)
- (2.01863 x VKORC1 AA) - (0.50836 x CYP2C9*1/*2)
- (0.97546 x CYP2C9*1/*3) - (1.10204 x CYP2C9*2/*2)
- (1.74761 x CYP2C9*2/*3) - (3.40061 x CYP2C9*3/*3)
- (0.03686x age) - (0.27698 x female)
- (0.06992 x potentiating drugs)]2 
where: age (in years)
female = 1, male = 0
potentiating drugs = the number of drugs taken which can increase
the INR
Zhu etal, 2007:
In dose (mg/day) = [1.35 - (0.008 x age) + (0.116 x gender) + (0.004 x weight)
- (0.376 x VKORC1 AA) + (0.271 x VKORC1 GG)
- (0.307 x CYP2C9*2) - (0.318 x CYP2C9”3)] 
where: In = log of dose
age (in years) and weight (in pounds)
gender = 0 for female and 1 for male
CYP2C9 = input 0, 1 or 2 for the number of *2 and *3 alleles
VKORC1 AA = input 0 for GG, 0 for GA and 1 for AA
VKORC1 GG = input 1 for GG, 0 for GA and 0 for AA
Gage etal, 2008 (clinical algorithm):
Dose (mg/day) = exp [0.613 + (0.425 x BSA) - (0.0075 x age)
+ (0.156 x Afro American) + (0.216 x target INR)
- (0.257 x amiodarone) + (0.108 x smokes)
+ (0.0784 x DVT/PE)] 
where: exp = exponential function
age (in years) and BSA (in m2)
Afro American = 1 other = 0
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amiodarone = 1 (present) or 0 (absent)
smokes = 1 for a smoker or 0 for a non-smoker
DVT/PE = 1 (if initial diagnosis was DVT or PE), others = 0
IWPC, 2009 (clinical algorithm):
Dose (mg/week) = [4.0376 - (0.2546 x age) + (0.0118 x height)
+ (0.0134 x weight) - (0.6752 x Asian)
+ (0.4060 x Afro American) + (0.0443 x mixed race)
+ (1.2799 x enzyme inducer drugs) - (0.5695 x amiodarone)]2
where: age (in decades), weight (in kilos) and height (in centimetres)
Asian, Afro American or mixed race = 1, others = 0
CYP enzyme inducers = phenytoin, carbamazepine or rifampicin
amiodarone = 1 (present) or 0 (absent)
Zambon etal, 2011 (clinical algorithm):
Dose (mg/week) = [2.9241 - (0.01943 x age) + (1.94651 x BSA)]2
where: age (in years) and BSA (in m2)
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Appendix XII Example of a VK0RC1 dot plot
VKORC1 allelic plot
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Appendix XIII Example of a CYP2C9 *2 dot plot
CYP2C9 *2 allelic plot
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•  Homozygous "1/r1
•  Heterozygous *1/*2
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Appendix XIV Example of a CYP2C9 *3 dot plot
CYP2C9 *3 allelic plot
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Appendix XV Example of a CYP4F2 dot plot
CYP4F2 allelic plot
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